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In recent years, Thymic stromal lymphopoietin (TSLP) has emerged as a master switch for actuating 
cellular inflammation and local remodeling in asthmatic airways. Originally discovered as a growth 
and proliferation factor of the B cells, thymic stromal lymphopoietin (TSLP) is now implicated in 
immune system related effects on several cells including B cells, basophils, CD4+, CD8+ and natural 
killer T cells, dendritic cells, eosinophils, epithelial cells and mast cells. The structural and immune 
cells express TSLP at the site of allergen entry in the airways. TSLP regulates the T helper 2 (Th2) 
cells humoral immunity by upregulation of a ligand, OX40L, on the surface of the dendritic cells 
(DCs), which activates the naive Th0 cells to active Th2 lymphocytes. The role of TSLP in the 
promotion of Th2 responses has been panoptically studied in the context of several allergic disorders. 
The experimental work in this thesis is focused on the creation of tools to study/manipulate the 
signaling of murine TSLP/TSLPR system and thus help us in a better understanding of targeting the 
TSLP induced signal transduction during allergic inflammation. The studies involved development 
of a TSLPR expressing luciferase gene based murine cellular model, as well as an inducible TSLP 
secreting epithelial-dendritic cell based model as readouts. The process involved production, 
purification and characterization of murine TSLP (mTSLP) as a fusion protein with maltose binding 
protein (MBP) i.e. mTSLP-MBP and mutant I37E mTSLP-MBP. Exo-mTSLPR domain soluble 
protein was also produced as a competitive inhibitor and it was then used to generate an anti murine 
TSLPR antibody for the detection of mTSLPR receptors on the cells. These tools have been 
successfully tested on the readout systems as mentioned above. The I37E mTSLP-MBP mutant 
showed partially competitive effects in the cellular readouts. The mTSLPR showed an effective 
blocking of mTSLP induced signaling. The anti mouse TSLPR antibody could bind to the TSLPR 
receptors on the cells but it was found to be non inhibitory in nature. 
By generating the above mentioned inhibitory proteins, novel strategies have been developed to 
analyze and specifically inhibit TSLP induced immunological activation. The results from these 
cellular model based studies are in agreement with those obtained from studies involving similar 
molecules designed for studying human TSLP-TSLPR system in our group in the past. These results 
cumulatively prove that a successful blockade of the human/murine TSLP-TSLPR system is possible. 
These results offer an insight into multifaceted roles of TSLP and could potentially pave the way for 






In den letzten Jahren trat TSLP (Thymic Stromal Lymphopoietin) als ein Hauptakteur in der 
Auslösung von zellulären Entzündungsreaktionen sowie in asthmatisch bedingten Umbauprozessen 
in den Atemwegen hervor. TSLP wurde ursprünglich als Wachstums- und Proliferationsfaktor von 
B-Zellen identifiziert. Heute weiß man, dass TSLP in Effekte des Immunsystems auf verschiedene 
Zellen wie B-Zellen, Basophile, CD4+-, CD8+- und Natürliche Killer-T-Zellen, Dendritische Zellen, 
Eosinophile, Epithelzellen sowie Mastzellen involviert ist. In den Atemwegen wird TSLP in 
Struktur- und Immunzellen am Ort des Allergeneintritts exprimiert. Dabei reguliert TSLP die 
humorale Immunantwort von Typ2-Helfer-Zellen (Th2-Zellen) über die Aktivierung des OX40-
Liganden auf der Oberfläche von Dendritischen Zellen, wodurch wiederum naive T-Helferzellen zu 
aktiven Th2-Lymphozyten aktiviert werden. Im Kontext verschiedener allergischer Erkrankungen 
wurde die Rolle von TSLP in der Promotion der Th2-Antwort umfassend studiert. Der 
experimentelle Teil der vorliegenden Arbeit war fokussiert auf die Entwicklung von Werkzeugen, 
um die Signalprozesse des murinen TSLP/TSLP-Rezeptor-Systems zu studieren bzw. manipulieren, 
mit dem Ziel, die TSLP-induzierten Signal-Transduktionsprozesse während der allergischen 
Reaktion besser zu verstehen und zu beeinflussen. Die Studien beinhalteten die Entwicklung von 
„Readout“-Systemen, einerseits eines Luziferase-Reportergen-Assays gekoppelt an die TSLPR-
Expression in einem murinen Zellmodell sowie andererseits ein induzierbares dendritisches 
Epithelzellmodellsystem zur Sekretion von TSLP. Die Arbeit beinhaltete die Produktion, 
Aufreinigung und Charakterisierung von murinem TSLP als Fusionsprotein mit Maltose-bindendem 
Protein (MBP), dem mTSLP-MBP und der Mutante I37E mTSLP-MBP. Die Extrazelluläre Domäne 
des TSLP-Rezeptors (exo-mTSLPR-Domäne) wurde zudem als kompetitiver Inhibitor produziert 
und zur Generierung von monoklonalen anti-murin-TSLPR-Antikörpern zur Detektion des 
zellulären TSLPRs genutzt. Diese Werkzeuge wurden erfolgreich mit den vorgenannten „Readout“-
Systemen getestet. Der mTSLPR zeigte eine effiziente Blockierung der durch mTSLP induzierten 
Signalübertragung. Der generierte monoklonale Maus-mTSLPR-Antikörper wies eine positive 
Bindung an den zellulären TSLPR auf und zeigte keine inhibitorischen Effekte auf die 
Signalübertragung.Mit der Generierung der inhibitorisch wirksamen TSLP-Proteine konnten neue 
Strategien zur Analyse sowie spezifischen Inhibierung der TSLP-induzierten Immunreaktion 
entwickelt werden. Die Ergebnisse aus den Zellmodell-basierenden Studien der vorliegenden Arbeit 
stimmen mit vergangenen Studien der Arbeitsgruppe überein, in welchen ähnliche Moleküle 
konstruiert wurden, um das humane TSLP/TSLPR-System zu untersuchen. Insgesamt beweisen 
diese Ergebnisse, dass eine erfolgreiche Blockade des humanen/murinen TSLP/TSLPR-Systems 
möglich ist. Zudem gibt die vorliegende Arbeit einen Einblick in die vielseitige Rolle von TSLP und 
könnte möglicherweise den Weg in die therapeutische Manipulierung im Rahmen von allergischen 







Thymic stromal lymphopoetin (TSLP) has emerged as a central player in the pathogenesis of allergic 
Asthma (West et al., 2012). Produced by various allergen-challenged cell types, amongst them 
epithelial cells, fibroblasts and mast cells, it instructs dendritic cells to favor a T helper 2 (Th2) type 
immunological response which is crucial in the development of Asthma (Al Shami, et al., 2005). The 
essential functions of TSLP in this context are as yet only vaguely understood and need to be studied 
thoroughly in order to unveil their pharmacological potential. 
Murine TSLP (mTSLP) was first recognized as a bioactive component in the conditioned medium 
supernatants from a mouse thymic stromal cell line cell Z210R.1 (Friend et al., 1994). This 
supernatant was observed to support growth and proliferation of a pre-B cell line. mTSLP behaved 
similar to IL-7 and could stimulate thymocytes and promote B-cell lymphopoiesis and was initially 
studied as a B-cell growth factor (Levin et al., 1999). Subsequently, expression and cloning lead to 
the revelation that the mTSLP is a member of the hematopoietic cytokine family (Sims et al., 2000). 
mTSLP consists of 140 amino acids (121 correspond to the mature murine TSLP and 19 correspond 
to signal peptides) (Sims et al., 2000) and is a 15 kDa protein coded by gene located on chromosome 
18 (search data from NCBI Gene). mTSLP consists of seven cysteine residues and three sites for N-
linked glycosylation.  
A human homolog, human TSLP (hTSLP), was later identified using database search methods 
(Quentmeier et al., 2001, Reche et al., 2001). Sequence prediction revealed a similar four-helix 
structured cytokine with two N-glycosylation sites and six cysteine residues. hTSLP gene is located 
on chromosome 5q22, interestingly close to a gene cluster encoding Th2-related cytokines such as 
Inerleukin-4, 5, 9 and 13 (IL-4, IL-5, IL-9, and IL-13) (Loots et al., 2000). hTSLP and mTSLP exhibit 
poor homology with only 43% amino acid identity (Sims et al., 2000). TSLP is expressed mainly in 
the lungs, skin, and gut (Reche et al., 2001). The human TSLP sequence is 740 bp long, and encodes 
a protein of 159 amino acids. The mature human TSLP protein and the signal sequence are 
respectively 131 and 28 amino acid long (Sims et al., 2000). Human TSLP contains two sites for N-
linked glycosylation, which are not conserved between mouse and humans. While human TSLP 
molecular weight (MW) is predicted at 14.9 kDa, practically, it resolves at 23 kDa, suggesting that 
it is indeed glycosylated. The 6 cysteines present in the murine TSLP are conserved in the human 
TSLP sequence. Disulfide bonds between cysteine pairs are also conserved between man and mouse 
(Quentmeier, 2001, Reche et al., 2001) As a reason, human and murine TSLP share a significant 
degree of functional homology (Reche et al., 2001, Sims et al., 2000). 
TSLP receptor (TSLPR) is a heterodimeric receptor complex comprising of TSLPR and the IL-7α 




family and binds to TSLP at low affinity. A combination of TSLPR and IL-7α chain results not only 
in high-affinity binding but also in STAT1, STAT3 and STAT5 activation (Pandey et al., 2000, Park 
et al., 2000, Reche et al., 2001, Wohlmann et al., 2010) (see Fig. 1.1.). TSLPR alias Cytokine receptor 
like factor-2 (CRLF2) is expressed in heart, skeletal muscle, kidney and liver, as well as in asthma-
inducing dendritic cells (Reche et al., 2001, Liu et al., 2007). 
Asthma bronchiale is a globally prevalent major health concern (Vercelli, 2008, Concepts, 2006). It 
is a chronic inflammatory disorder characterized by variable and recurring symptoms like airway 
obstruction, hyper-responsiveness, goblet cell hyperplasia and airway remodeling (Umetsu et al., 
2006, Kim et al., 2010). Asthma is associated with genetic susceptibility in combination with 
environmental factors and has been linked to a dysregulated Th2 immune response (Humbert et al., 
1999, Cookson, 2000). A dysregulated Th2 polarization and expansion has been implicated to play 
a critical role in the development of airway hyperresponsiveness during asthma (Kim et. al., 2013) 
and various mechanisms which are responsible for it are being investigated upon. During atopic 
Asthma, TSLP is produced by epithelial and smooth muscle cells and is involved in the induction of 
an inflammatory Th2 response. (Soumelis et al., 2002, Watanabe et al., 2004). Exposure to allergens 
(Agrawal et al., 2012, Leyva-Castillo et al., 2013) or viruses (Fontenot et al., 2009) triggers mucosal 
epithelial cells or skin cells to produce TSLP (Shikotra et al., 2011). TSLP initiates the innate phase 
of allergic immune responses by activating the immature dendritic cells (DCs) to produce 
chemokines IL-8 and eotaxin-2, as well Th2-attracting chemokines. It also co-stimulates mast cells 
to produce IL-5 and IL-13 as well as Granulocyte macrophage colony-stimulating factor (GM-CSF) 
and IL-6 (Ito et al., 2005, Gilliet et al., 2003, Ito et al., 2012). TSLP-activated DCs mature and migrate 
into the draining lymph nodes to initiate the adaptive phase of allergic immune response. TSLP-
activated DCs express the OX40 ligand (OX40L), which triggers the differentiation of allergen-
specific naive T cells into inflammatory Th2 cells (Chen et al., 1999, Miura et al., 2005, Siddiqui et 
al., 2010, Kaur et al., 2012). The cytokines produced by the inflammatory Th2 cells (IL-4, IL-5, IL-
13, and TNF-α) initiate allergic inflammation by triggering IgE and mucus production as well as 
eosinophilia (Reche et al., 2001, Soumelis et al., 2002, Liu et al., 2007). Notably, it has been shown 
that the local blockade of TSLP receptor alleviated allergic disease by regulating the airway dendritic 
cells (Shi et al., 2008). Nguyen et al. have shown that activated pulmonary regulatory T cells (Treg) 
express the TSLP receptor and respond to TSLP stimulation by activation of STAT5 (Nguyen et al, 
2010). TSLP inhibits Treg suppressive activity by impairing IL-10 production. They demonstrated 
that in human allergic asthmatic subjects, pulmonary Treg exhibited a significant decrease in 
suppressive activity and IL-10 production compared to healthy control and non-allergic asthmatic 
counterparts. These functional aberrations were attributed to the elevated TSLP expression in 
bronchoaveolar lavage (BAL) fluid of allergic asthmatic subjects. From these findings it can be 
concluded that TSLP has a possible role in the regulation of suppressive activities of Treg. Strong 




subsets during allergic airway inflammation. Inhibition of Treg function by TSLP may provide a 
novel pathologic mechanism for dampening tolerogenic immune responses in inflamed asthmatic 
airways.TSLP signalling relies on the activation of signal transducer and activator of transcription 
(STAT) proteins. It has been shown that the TSLPR utilizes both STAT5 and STAT3 to regulate 
signals for the expression of target genes (Isaksen et al., 2002, Reche et al., 2001, Pandey et al., 
2000). It has also been found that TSLP activates STAT1 in murine pro B cells (Wohlmann et al., 
2010). Both STAT3 and STAT5 have been shown to be the regulators of IL-17 expression and Th17 
cell development (Yang et al., 2011). Since TSLP is involved in the pathophysiology of inflammatory 
diseases and is related to regulatory T cells (Treg) via STAT signalling, it appears an interesting 
option to block STAT function to interfere with TSLP activity. 
 
1.2. Murine Thymic Stromal Lymphopoietin (mTSLP): mode of action  
mTSLP is an mIL-7-like cytokine and belongs to the IL-2 cytokine family. mTSLP was characterized 
as a 121-amino acid containing 4-helix bundle (Verstraete et al., 2014). This cytokine was originally 
discovered in murine thymic stromal cell line supernatants, which supported B-cell development in 
the absence of IL-7 (Sims et al., 2000). Polymorphisms of the TSLP gene have been associated with 
allergic asthma in humans (Sims et al., 2000). mTSLP and the other members of the IL-2 family 
member signal via the JAK-STAT pathway involving STAT1, 3 and 5 (Wohlmann et al., 2010, 




Fig. 1.1. Receptors for γcfamily cytokines and TSLP. The figure shows the receptors for Interleukin-2 (IL-2), IL-4, IL-
7, IL-9, IL-15, IL-21 and thymic stromal lymphopoietin (TSLP). Only IL-2 and IL-15 have three receptor chains. The 
receptors for these receptors share the γc-chain. The IL-7 and TSLP share the IL-7Rα chain, thus only TSLP does not signal 
via γc. The receptor for each γc family cytokine activates the Janus kinase 1 (JAK1) and JAK3 and further STATs. The 




The mechanism of TSLP action involves the activation of the dendritic cells upon challenge with 
allergens on the mucosal surface leading to the secretion of TSLP from the basal epithelium (Lu et 
al., 2009, Ziegler et al., 2006), see Fig. 1.2. 
 
 
Fig.1.2. A cellular scheme showing mechanism of TSLP action. The pollens/allergens activate the secretion of TSLP 
from the basal epithelial layer. TSLP activates the dendritic cell maturation i.e. production of OX40L on the cell surface. 
The receptors for these ligands are present on the naive T cells. The dendritic cells migrate to the lymph nodes and activate 
the naive T cells to transform into Th2 cytokine producing cells.This occurs via OX40L-OX40R interactions between 
dendritic cells and T cells respectively. The mature T cells reach the site of inflammation and secrete Th2 cytokine. 
Modified from: (Lambrecht et al., 2012) 
 
The dendritic cells which have been activated differ from the naive ones in the expression of surface 
OX40L. The OX40L has critical role in the activation of the naive T cells in the lymph nodes (Chen 
et al., 1999). The dendritic cells migrate to the lymph node and activate the naive T cell via OX40L-
receptor interaction thus transformin the naive T cells into Th2 cytokine secreting cells (Ito et al., 
2005).  
 
1.3. Effects of TSLP on various immune cells 
Several cells have been found to respond to TSLP because of the presence of TSLP receptor on them 
or because of an indirect response created by chemokines/receptor expression leading to activation 
or suppression. The table 1.1 below summarizes various cellular responses and salient effects on the 





  Table 1.1. Effect of TSLP on various immune cells. 
 




CD4+ T-cell homeostasis in co-culture (T-cell proliferation but no 
differentiation) (Watanabe et al., 2005). 
TSLP-stimulated DCs primed CD4+ T cells in an antigen-specific manner 
which lead to the differentiation of T cells to Th2 cells (produced IL-4, IL-
5, IL-13, and tumor necrosis factor TNF-α, without IL-10 production) 
(Soumelis et al., 2002). Leads to an enhanced levels of MHC class II, CD40, 
CD86, CD54, CD80, CD83, IL-8, eotaxin-2, Thymus and activation-
regulated chemokine, C-C motif chemokine 17 (TARC) /CCL17), 
Macrophage derived chemokine (MDC/CCL22), Chemokine (C-C motif) 
ligand (I-309/CCL1) (Li et al., 2010). In the absence of IL-12, TSLP 
induced OX40 ligand (CD134) (Ito et al., 2005). 
 
CD4+ and CD8+ T 
cells 
 
Increased proliferation of T and B cells in γc /TSLPR double deficient mice 
(Al-Shami et al., 2004). Proliferation and Th2 differentiation of naive CD4+ 
T cells by IL-4 gene transcription and feedback loop (Omori et al., 2007, 
Astrakhan et al., 2007, Rochman et al., 2007). 
Upregulation of TSLPR on Th 17, CD4+ T (Th2 ) cells and human CD8+ T 
cells (Tanaka et al., 2010, Akamatsu et al., 2008, Shane et al., 2014). 
STAT5 dependent upregulation of survival protein B-cell lymphoma 2 
(Bcl-2) in both CD4+ and CD8+ T cells (Kitajima et al., 2011, Y. Rochman 





B-cell lymphopoiesis (Friend et al., 1994, Levin et al., 1999), pre-B cells 
proliferate in response to TSLP (Vosshenrich et al., 2003).  
Aberrant TSLP signaling leads to significant impact on B cells, as defined 
by association of TSLPR mutations with a subtype of B cell leukemia 
(Chapiro et al., 2010, Reuther, 2010, Tasian & Loh, 2011). Increased 
systemic TSLP leads to aberrant B-cell development and function, leading 
to autoimmune hemolytic anemia (Astrakhan et al., 2007, Iseki et al., 2012) 
 
Mast cells  
 
 
Increased IL-5,6,8,10,13, GM-CSF, Chemokine ligand 1 (CCL1) and 
decreased TGF-β levels (Allakhverdi et al., 2007, Gilfillan et al, 2006).IL-
1 and TSLP secretion from epithelial cells activated Th2 cytokine 




Natural killer T 
cells (NKT cells) 
 
Enhanced cytokine production from NKTcells e.g. increased IL-4 and 13 
(C. C. Hui et al., 2011, Allakhverdi et al., 2007, Nagata et al., 2007, Wong 
et al., 2009, Wu et al., 2010). TSLP induced IL-10 production and NK cell 





Increased TARC (Ying et al., 2012) and CD80 surface expression (Hirano 
et al., 2011). 
 
T regulatory cells  
 
 
TSLP generated tolerogenic DCs lead to the differentiation of regulatory T 
cells (Tregs) (Besin et al., 2008, Iliev et al., 2009, Watanabe et al., 2005) 
while in certain diseases, it hindered the production and maintenance of 
forkhead box P3 (FOXP3+), Tregs in vivo (Duan et al., 2010, Lei et al., 






Increased eosinophilpoiesis and basophilopoiesis (Siracusa et al., 2013). 
Increased cytokine and chemokines levels of IL-5, IL-13, GM-CSF, and 
chemokines (CCL22, CCL17, CXCL8, CCL1) (Allakhverdi et al., 2009),  




Enhanced CD69, CD62L, CD11b, CD123, IL-33R, IL-18R surface 
expression (Siracusa et al., 2011, Tsai et al., 2012). 
Enhanced development of an IL-3-independent subset of basophils which 
plays a role in promoting Th2-type responses (Siracusa et al., 2011, Sokol 
et al., 2009).  
Leads to haemotopoesis (Siracusa, et al., 2013). 




Increased survival and adhesion, increased surface expression of CD18, and 
increased secretion of ICAM-1, CXCL1, CCL2, CXCL8, IL-6 and  
decreased L-selectin (Wong et al., 2010).  
Induction of eosinophil extracellular traps and extrusions of mitochondrial 
DNA toxic granule molecules released in response to infections (Morshed 
et al., 2012). 
 
Airway smooth 
muscle cells  
 
Increased secretion of IL-6, CXCL8, CCL11 (Smelter et al., 2010) and 





1.4. Molecular structure of murine TSLP/TSLPR complex 
a. b.  
Fig.1.3. a. The structure of mTSLP and b. mTSLP-mTSLPR interactions. The murine TSLP comprises of 4 helices α-
A, α-B; α-C and α-D. The cytokine interacts with the mTSLP receptor at various hot spots. An important hot spot identified 
on the interactive interface is mediated by Ile37 (see Fig 1.3 b. encircles red) (modified from Verstraete et al., 2014) 
The X ray crystallographic structure of murine TSLP and TSLPR interactions was revealed by 
Verstraete et al., 2014. They used HEK293S MGAT1−/− cells to coexpress mouse TSLP (mTSLP)-
TSLPR (mTSLPR) binary complexes with homogeneous N-linked GlcNAc2Man5 glycan trees. 
(Verstraete et al., 2014). They produced the mouse IL-7Rα (mIL-7Rα) in Escherichia coli coupled 
to refolding in vitro and then post purification they assembled the mouse TSLP–TSLPR–IL-7Rα 
ternary complex by mixing purified TSLP–TSLPR complex with a molar excess of purified 
recombinant IL-7Rα. The accessible N-linked glycans were removed by endoglycosidase H (EndoH) 
treatment. The ternary TSLP-TSLPR complex showed binding similar to other members of the IL-2 
family. The cytokine interacts with the two receptors chains with the cytokine-binding epitopes 
available at the D1-D2 junctions of each receptor (see Fig.1.3.b). TSLP binds between the TSLPR 
and IL-7Rα on surfaces, in a T shaped assembly. TSLP exhibits a short-chain four-helix bundle fold 
resembling IL-7, despite the low sequence homology between the two cytokines, and has an extended 
helix A at the N terminus and markedly shorter B and C helices (Fig. 1.3 a). The core residues and 
cysteines involved in the disulfide bonds (Cys25-Cys98, Cys57-Cys63 and Cys78-Cys121) are 
strongly conserved and this suggests that the observed fold can be generalized to all mammalian 
TSLPs. An ordered water molecule is located in the in the TSLP core and is coordinated by a 
conserved triad of residues (Thr71, Thr90 and Trp132). Unlike other IL-2 family cytokines which 
possess conformational plasticity, TSLP core remains largely invariable.TSLPR bears a structural 
and evolutionary resemblance to the common cytokine receptor γ chain (γc) and IL-13Rα1. TSLPR 
carries a conserved PSxW(S/T) sequence cassette instead of the WSxWS sequence fingerprint in 
other type I cytokine receptors. TSLPR also showed a disulfide-bridge network, with a cis peptide 
bond between Cys168 and Cys169. A single well-conserved N-linked glycosylation site in 
mammalian TSLPR, N-acetylglucosamine (GlcNAc) glycan moiety at Asn53 was located in TSLPR 
crystal form. This GlcNAc residue is involved in the interaction of the with residues located in strands 




to both the TSLP–TSLPR interface (site I) and the TSLP–IL-7Rα interface (site II). The TSLP–
TSLPR interface was characterized by the presence of several polar interactions which indicate a 
highly specific interaction. This is perhaps the reason for the poor conservation of site I interacting 
residues in mouse and human TSLP and TSLPR orthologs and the lack of species cross-reactivity 
among TSLP orthologs. An important hot spot identified on the interactive interface is mediated by 
Ile37 (see Fig. 1.3 b. encircled red) protruding from the π-helical turn on helix A of TSLP into a 
conserved hydrophobic pocket in the D1-D2 junction of IL-7Rα and is defined by the residues 
Leu101, Ile102, Tyr159, Tyr213 and Phe214. 
 
1.5. Role of TSLP in diseases  
 
Since several different types of cells are associated with various responses to TSLP, it can cause Th2 
type inflammation through numerous pathways. The various studies in mouse models and humans 
have lead to the implication of TSLP in several disorders (see Fig.1.4) including allergic inflammation, 
infection, cancer and autoimmunity. The various disorders associated with TSLP and its role in these 
diseases has been described below.  
 
Fig. 1.4. Diseases in which TSLP has a direct or suspected role. TSLP is involved in several diseases and in some its role is being 
probed. (Takai, 2012) 
Atopic Dermatitis: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 
approximately 20% infants and young children in the USA (Boguniewicz et al., 2011). TSLP was 
found to be highly expressed in acute and chronic lesional AD patients while its level were 
undetectable in non lesional AD patients (Soumelis et al., 2002). The migration and activation of the 
Langerhans cell (LC) was observed in human AD lesions and TSLP was implicated for the increased 
proliferation and induced migratory behavior in LC cultures. These LCs could prime co-cultured naive 




of TSLP in mice skin induced the phenotypic features of AD (Yoo et al., 2005). Single nucleotide 
polymorphisms (SNPs) in the TSLP gene in AD suggested an evident linkage between them. It was 
reported that the subjects with AD were more sensitive to Th2-polarized diseases and had a 
background patient history of asthma, food allergy, or both (Gao et al., 2010). TSLP was also over 
expressed in the skin of patients suffering from Netherton syndrome (NS), which is characterized by 
lesions and allergic symptoms resulting from mutations in the serine peptidase inhibitor Kazal-type 5 
(SPINK5) gene, that encodes the serine protease inhibitor lymphoepithelial Kazal type-related 
inhibitor (LEKTI) (Briot et al., 2009). In a model of NS, SPINK5 knockout (SPINK5 −/−) mouse, the 
absence of LEKTI lead to uncontrolled activity of the serine protease kallikrein 5, resulting in activation 
of activated protease-activated receptor 2 (PAR-2) and stimulation of nuclear factor κB (NF-κB)-
mediated TSLP overexpression (Kouzaki, et al., 2009). TSLP expression was reduced though 
inflammation still occurred in the SPINK5/PAR-2 double-knockout mice (Briot et al., 2010). It has been 
reported that during steady state in the skin, TSLP expression is negatively regulated by retinoid X 
receptors.(RXRs) which is supported by the fact that keratinocyte-specific extirpation of the RXR 
isotypes (RXRα and RXRβ) lead to an upregulation of TSLP and therefore an AD-like skin 
inflammation (M. Li et al., 2006). The RXRs heterodimerize with several nuclear receptors including 
the vitamin D receptors. The administration of vitamin D/analogs lead to an upregulation of TSLP 
leading to dermatitis (M. Li et al., 2006, Mei Li et al., 2009). The tendency of the patients suffering 
from AD of developing allergic rhinitis (AR) and asthma later in life is known as atopic march and 
TSLP has been implicated in this event (Bieber, 2010, Tang, et al, 2012). TSLP is thought to be a key 
factor causing the progression from AD to AR and then further to asthma. This has been shown by 
various AD mouse models that induced TSLP expression in keratinocytes resulted in subsequent allergic 
airway inflammation following intranasal challenges (Demehri et al., 2009, Jiang et al., 2012, Leyva-
Castillo et al., 2013, Zhang et al., 2009). It has been also observed that even in absence of systemic TSLP, 
the intradermal administration of TSLP initiates AD to asthma transition (Han et al., 2012). It was also 
reported that IL-13 in conjunction with TSLP lead to skin fibrosis via stimulation of fibrocyte collagen 
production.in atopic dermatitis (Oh et al., 2011). 
 
Asthma, Chronic Obstructive Pulmonary Disease (COPD) and other lung related diseases: The initial 
findings showing elevated TSLP in AD and the initiation of inflammatory Th2 responses by TSLP 
suggested a potential hypothetical role for TSLP also in allergic airway disease (Soumelis et al., 2002). 
This hypothesis was strongly supported with the reports of presence of TSLP mRNA in human lung 
fibroblasts, bronchial epithelial and smooth muscle cells (Soumelis et al., 2002) and the aberrant expression 
of TSLP in several respiratory disorder (Kamekura et al., 2009, Kimura et al., 2011, Semlali et al., 2010, 
Shikotra et al., 2011, Xu et al., 2010, Ying et al., 2012). Ying et al used in situ hybridization and immuno-
histochemistry to examine the expression of TSLP mRNA, Th2 and Th1-attracting chemokines and their 




from this study indicated a significant increase in the number of CD4+ chemokine receptor (CCR4+) T cells 
within the submucosa, TSLP mRNA expression, enhanced levels of Th2-attracting chemokines CCL17, 
CCL22 and Th1-attracting chemokine C-X-C motif chemokine 10 (CXCL10), in asthmatic subjects as 
compared with the controls. Similarily, TSLP mRNA expression in the epithelial macrophages, as well as 
submucosal endothelial cells and neutrophils was also significantly higher in the asthmatics as compared 
to the healthy controls. The expiratory volume in one second (FEV1) showed an inverse correlation with 
the expression of TSLP, thereby proving that TSLP is responsible for the pathophysiology of asthma and 
deteoration in lung volume functions. The lung epithelium and submucosal patient samples from other 
diseases such as chronic obstructive pulmonary disease (COPD) patients also contained a higher number 
of TSLP mRNA positive cells and TSLP levels in the bronchoalveolar lavage (BAL) samples as compared 
to healthy individuals (Semlali et al., 2010, Shikotra et al., 2011, Ying et al., 2012). The TSLP expression 
levels can vary from one patient to another but a direct correlation between the levels of Th2 cytokine and 
the chemokine expression and an inverse relation with the lung function has been established (Shikotra et 
al., 2011, Ying et al., 2008). The biopsies in the patients suffering from atopic rhinitis have shown enhanced 
TSLP levels in the nasal epithelium which has been has also linked with the infiltration of the epithelial 
tissue with the eosinophils and production of Th2 cytokine (Kamekura et al., 2009, Kimura et al., 2011, 
Mou et al., 2009 , Xu et al., 2010). The genetic studies have also shown that single nucleotide 
polymorphisms at the TSLP genomic locus in several ethnic populations were linked with atopy and 
vulnerability to asthma (Bunyavanich et al., 2011, 2015, Harada et al., 2009, 2011, Hunninghake et al., 
2010, Torgerson et al., 2011). For example, Harada et al. showed in their studies that such a SNP present 
at TSLP genomic locus leads to a new binding site for activator protein 1 (AP-1) transcription factor-
binding and possibly enhanced transcription of TSLP. There are other genes that may also be linked to 
TSLP activity in asthma. It has been observed that epistasis between SPINK5 and TSLP may contribute to 
childhood asthma. The study by Myers et al. has a clinical relevance that the therapeutic effects of anti-
TSLP therapy in asthmatic patients might be dependent on SPINK5 genotype due to epistasis between  
SPINK5 and TSLP, which contributes to childhood asthma (Myers et al., 2014). The role of TSLP in 
disease is also established in several mouse models. The surfactant protein C (SPC)-TSLP mouse model 
has also supported the fact that TSLP is involved in asthma. In such a mice, constitutive TSLP expression 
occurs in the lung epithelium under control of the SPC promoter (Zhou et al., 2005, Headley et al., 2011) . 
These mice developed asthma-like symptoms such as eosinophil and Th2 CD4+ T infiltrated lungs, 
remodeling of the airway pathway and airway hyper-responsiveness with enhanced levels of IL-4 and IL-
13 (Headley et al., 2009, Zhou et al., 2008). The BAL fluid and the lungs of the OVA/alum allergic airway 
inflammation mice models contain significant level of TSLP post ovalbumin (OVA) challenge. The 
disease symptoms could be restricted by blocking the TSLP activity by the use of anti TSLP or anti TSLPR 
antibody (Al Shami et al., 2005, Shi et al., 2008, Borowski et al., 2013). Similar effects were noticed in an 
OVA-mouse model of allergic rhinitis where blocking TSLP activity lead to repressed asthma symptoms 




dendritic cells which prime the naive Th2 cells to Th2 cytokine producing cells. This is in orchesrated by 
expression of a costimulatory molecule OX40L on the surface of mature dendritic cells and secretion of 
chemokines such as CCL17 and CCL21. (Allakhverdi et al., 2007, Bleck et al., 2010, Soumelis et al., 2002, 
Li et al., 2010, Seshasayee et al., 2007; Shi et al., 2008; Zhang et al., 2011, Zhou et al., 2005). TSLP also 
promotes the development of thymic Tregs in vitro (Hanabuchi et al., 2012, R. Mazzucchelli et al., 2008 , 
2012). In allergic airway disease, TSLP has been shown to inhibit IL-10 mediated Treg function and 
formation of inducible Tregs against exogenous antigens (Nguyen et al., 2010). A TSLP-dependent 
inhibition of pulmonary Treg activity was shown in the BAL fluid from asthmatics (Nguyen et al., 2010). 
An interfering role of TSLP in tolerance was observed in an OVA allergen model where it inhibited the 
generation of allergen-specific Tregs (Lei et al., 2011). In similar model, nucleotide-binding 
oligomerization domain-containing protein (Nod1 and Nod2) stimulation lead to curtailed tolerance 
towards OVA intranasal challenge correlating to TSLP- and OX40L levels (Duan et al., 2010). Also post 
Nod2 stimulation, the loss of TSLP signaling was found to be correlated with an enhanced antigen-specific 
FOXP3+ T cells (Duan et al., 2010). Several different kind of allergic stimuli like IL-4, IL-13, TNF-α, IL-
1, bacterial peptidoglycan, lipoteichoic acid, dsRNA, respiratory viruses, air pollutants and allergens induce 
NF-κB-dependent expression of TSLP (Lee et al., 2007), by lung-derived parenchymal cells and immune 
cells (Allakhverdi et al., 2007, Bleck et al., 2015, Lee et al., 2008, Kashyap et al., 2011, Kato et al., 2007, 
Kouzaki et al., 2009, Smelter et al., 2010, Soumelis et al., 2002; Zhang et al., 2007). A negative regulation 
of TSLP transcription by 9-cis-retinoic acid via retinoid X receptor (RXR) has been shown in the lung 
cells (Lee, et al., 2012). 
 
Sepsis: High mortality and morbidity has been observed in sepsis related multiorgan system failure. 
In a cecal ligation and puncture (CLP) murine model for sepsis cohorts were treated with neutralizing 
anti TSLP antibodies or isotype controls pre- CLP to ascertain the changes in mortality and survival, 
bacterial loads, cytokine levels, and neutrophil inflammatory functions. This study lead to the 
observations that the TSLP levels were at their peak after 6 h and could be detected uptil 48 h post 
CLP. The mice which were pretreated with neutralizing TSLP showed decreased death rate and 
bacterial load post CLP. An enhanced level of tumor necrosis factor α and oxidative burst as well as 
increased interleukin 17 and increased neutrophil numbers were noticed in .the septic mice pretreated 
with the anti-TSLP antibody as compared to their counterparts treated with the isotype controls. This 
study leads to a speculation that TSLP numbs the neutrophil response resulting in increased bacterial 
load and mortality (Kuethe et al., 2014). 
Intestinal Inflammation: TSLP has been found to be expressed in the gastrointestinal tract of the mouse 
and human. Its expression has been found to be affected by cytokines or microbial inducers (He et al., 
2007, Humphreys et al., 2008, Tanaka et al., 2010, Taylor et al., 2009, Zaph et al., 2007, Zeuthen,et 




biosynthesis) (Biton et al., 2011) or IκB kinase-β gene deletions (Zaph et al., 2007) affect the gut 
mucosa with low expression of TSLP mRNA. These mouse models exhibited enhanced vulnerability 
to Trichuris muris worm infections. TSLP expression was reduced in a mucin gene (Muc2) missense 
mutation mice and lead to an epithelial defect and spontaneous colitis (Eri et al., 2011). Polymorphisms 
in genes locus of TSLP and TSLPR have been found to be associated with the disorder eosinophilic 
esophagitis (EoE) (Rothenberg et al., 2010, Sherrill et al., 2010) . In disparity to the enhanced TSLP 
expression in EoE, decreased TSLP expression was observed seen in noninflamed colonic tissue the two 
differenct conditions of inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative 
colitis (UC) (Noble et al., 2008, 2010, Iliev et al., 2009, Spadoni et al., 2012; (Rimoldi et al., 2005). 
However, in the inflamed UC tissues from patients an upregulation of TSLP as compared to the 
noninflamed tissue from UC patients or normal controls was observed (Noble et al., 2008, Tanaka et 
al., 2010).  
Cancer: Recent studies have suggested a possible role of fibroblast secreted TSLP in the metastasis and 
growth of breast and pancreatic cancer tissues which also show Th2 infiltration and upregulation of Th2 
cytokines (De Monte et al., 2011, Olkhanud et al., 2012, Bodegom et al., 2012, Pedroza-Gonzalez 
et al., 2011). The shRNA knockdown of TSLP in these cancer cells lead to clones which showed reduced 
growth or metastasis (Olkhanud et al., 2011). Tumor progression and metastasis was also diminished in 
TSLPR-deficient mice with an injected breast cancer cell line as compared to the wild-type mice 
(Olkhanud et al., 2011). TSLP linked enhancement of Th2 cytokines can promote an increased survival 
of cancer cells, macrophage (M2) differentiation, and fibrosis (Aspord et al., 2007), (Joyce et al., 2009, 
Balkwill et al., 2012, Mantovani et al., 2008, Wynn, 2004). TSLP can alter the immunoregulatory 
environment by influx of Treg cells by migration caused due to CCL22 production in human breast 
cancer cells (Gobert et al., 2009, Menetrier-Caux et al., 2009). It has been observed that TSLPR is 
overexpressed in 5-10% patients suffering from childhood B-cell progenitor acute lymphoblastic 
leukemia (ALL) and approximately 60% of ALL cases in children with Down’s Syndrome (Ensor et al., 
2011, Russell et al., 2009, Mullighan et al., 2009, Tasian & Loh, 2011, Roll et al., 2010) thus suggesting 
the role of TSLP-TSLPR system in these disorders. 
Autoimmune Diseases: An inducible overexpression mice models of TSLP show that it can be associated 
with autoimmune diseases The inflammation driven cryoglobulinemic glomerulonephritis in these mice 
was associated with enhanced systemic polyclonal IgM and IgG production and deposition via a 
monocyte/macrophage dependent mechanism in the kidneys (Astrakhan et al., 2007, Taneda et al., 2001). 
Autoantibodies against red blood cells and autoimmune hemolytic anemia depending on CD4+ T cell 
and IL-4 was observed (Iseki, et al., 2012). The TSLP signaling ablation in a mouse model of 
autoimmune gastritis increased the severity of the disease (Nishiura et al., 2012). TSLP was found 
to be active in Th1/Th17-associated autoimmune diseases such as rheumatoid arthritis (RA) and multiple 




with reduced IL-17, IL-1β, and IL-6 cytokine levels but enhanced IFN-γ and IL-10 (Hartgring et al., 
2011). The role of TSLP in diabetes is evident as introduction of TSLP-treated bone marrow-derived 
DCs into a nonobese diabetic mice abrogated the development of diabetes (Besin et al., 2008). TSLP is 
produced and secreted by first semester trophoblasts and and has been linked with immune tolerance 
in maternal-fetal tolerance during pregnancy (Li et al., 2009). The tissue from normal pregnancies 
demonstrated a Th2 prejudice and had elevated levels of TSLP expression than the samples from 
miscarriages (Wu et al., 2010, Guo et al., 2010, Pu et al., 2012). 
 
1.6. Specific targeting of mTSLP/mTSLPR system 
 
Recent advances in deciphering the cellular and molecular mechanisms of Asthma have led to the 
recognition of novel targets for therapeutic strategies. (Seshasayee et al., 2007) provided direct in 
vivo evidence that TSLP and OX40 have critical roles in allergic inflammation. The blockade of 
interactions between OX40 surface-expressed on Th2 cells and OX40 ligand (OX40L) presented by 
TSLP-activated DCs using an OX40L-specific monoclonal antibody has been shown to inhibit Th2 
cell mediated immune responses in allergic inflammation models of nonhuman primate and mouse. 
These results in conjunction with various reports on the involvement of TSLP in allergic asthma (Shi 
et al., 2008, Borowski et al., 2013) serve as an encouragement to further explore the potential of 
TSLP signal transduction as a target for therapeutic approaches to ameliorate Asthma symptoms. In 
mouse, several strategies such as receptor targeted antibody approach have been used in the 
OVA/HDM model of asthma and transgenic TSLP receptor knockout models. The various studies 
have been summarized in table 1.2. It can be noticed that blocking TSLP activity leads to the 
reduction in levels of various allergic inflammatory markers and parameters suggesting tha TSLP is 
an important protein in the development of pathophysiology of these diseases. 
 
Table 1.2. Specific targeting of mTSLP pathway in mice (adapted from Watson et al., 2014) 




with and without  
OVA challenge 
 
TSLP overexpression in lungs, increased AHR, BAL eosinophils, 
lymphocytes, neutrophils, serum IgE, expression of co-stimulatory 
molecules in bone marrow DC, airway remodeling, subepithelial 
fibrosis, goblet cell hyperplasia, T helper type 2 cell-attracting 








TSLP receptor knock 
out monoclonal 
antibody (mAb) in 
OVA challenge mouse 
model 
 
Lack of TSLPR expression decreased these factors: 
Airway inflammation, goblet cell hyperplasia, AHR, BAL T-cell 
activation, eosinophils, lymphocytes, and monocytes neutrophils, 
BAL IL-4, IL-5, IL-10, IL-13, IFN-γ, IL-12 and serum IgE. 
(Dolgachev et al., 2009)  
 
TSLP receptor mAb in 
OVA challenge mouse 
model 
 
TSLP receptor blocking antibody lead to reduction in the following 
parameters: BAL TSLP, IL-5, IL-4, IFN-γ levels, BAL total cell 
count, eosinophils, lymphocytes, macrophages, DC co-stimulatory 
marker expression and serum IgE, mucus hypersecretion, 
peribronchiolar and perivascular connective tissue eosinophils (Shami 
et al., 2005, Zhou et al., 2005, Shi et al., 2008). 
 




OX40L blocking antibody reduced BAL eosinophils and lymphocytes, 
BAL IL-4, IL-5, IL-14, serum IgE and IgG1 (Seshasayee et al., 2007) 
 
TSLP mAb in house 
dust mice (HDM) 
mouse model 
 
TSLP blocking antibody reduced airway hyperresponsiveness  
(AHR), lung tissue TSLP protein and mRNA, BAL total cell count, 
eosinophils, lymphocytes,macrophages, neutrophils, airway 
remodeling, goblet cell hyperplasia, mucus hypersecretion, 
peribronchial collagen deposition, BAL IL-4, IL-13, IFN-g, 
Transforming growth factor (TGF-β1) and CD11c+ co-stimulatory 
marker expression (Chen et al., 2013) 
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2. Aims of the study 
1. To generate an effective Ba/F3 cell based luciferase assay readout system for analyzing and 
characterization of murine TSLP (mTSLP) signaling activities. 
2. To clone, express, purifiy and characterize the exo-domain of the TSLP receptor chain in the 
soluble form. 
3. To characterize the ligand binding properties of exo-mTSLPR-domain and the biological activity 
of the exo-mTSLPR-domain in a Ba/F3 cell luciferase assay.  
4. To produce and characterize the specific binding properties of a rat anti mouse-TSLPR antibody. 
5. To clone, express, produce and characterize mTSLP  
6. To identify, produce and characterize a potentially antagonistic TSLP variant. 
7. To confirm these antagonistic properties in the context of artificial cell based models and primary 
TSLP responsive dendritic cells to prove that the interference in the TSLP based communication 
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3. Materials and Methods 
 
3.1. Materials 
3.1.1. Equipment and accessories 
 
Table 3.1. List of used laboratory equipment 
Equipment Model Manufacturer 
Amaxa Nucleofactor Amaxa Nucleofactor I Lonza 
Bacterial incubator Incu-Line  VWR 
Benchtop centrifuges Rotina 380R 
Rotina 420R 
MF48 





Cell incubator Nuaire IBS Integra Biosciences 
Chromaotgraphy (Purification) Äkta Purifier Roche 
Chemiluminescence  
detection system 
G box Syngene VWR  
Clean bench Nuaire IBS Integra Biosciences 
Dry block heater QBD2 Grant 
Electrophoretic chamber Mini-PROTEAN Tetra system Bio-Rad 
Flow cytometer Partec/BD Diva Partec/BD 
Incubator shaker Ecotron Infors HAT 
Inverted microscope AE21 Routine Motic 
Luminometer Glo Max Promega 
Magnetic stirrer MR3001 Heidloph 
Mini centrifuge Sprout™ Biozym Scientific 
pH-meter 761 Calimatic Knick 
Platform shaker Titramax 100 Heidolph 
Precisions balance MC1 Analytik AC120S  Sartorius 
Spectral photometer NanoDrop 2000c Thermo Scientific 
Plate reader Sunrise Tecan 
Thermocyler AB2720 Applied Biosystems 
Vortex shaker - VWR 
Water bath Julabo 208 Julabo 
Western blot system Trans-Blot™ Cell Bio-Rad 
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Table 3.2. List of used laboratory consumables 
Equipment Manufacturer 
Cell culture plates (10cm) Greiner 
Combitips (1ml, 2.5ml, 5ml and 10ml) Eppendorf 
Nunc™ cell scrapers Thermo Scientific 
PCR plates ABgene® (96-Well) Thermo Scientific 
PCR tubes (0.2 ml) Biozym 
Plates (6-, 12-, 24- and 96-well) Greiner 
Plastic pipettes (2 ml, 5 ml, 10 ml, 25 ml) Greiner 
Nitrocellulose membrane Amersham/ Millipore 
Reaction tubes (0.5ml, 1.5ml and 2-ml) Eppendorf; Sarstedt 
Sterile filters Minisart® (pore size 0.2μm) Sartorius 
Syringes Injekt® (1ml,5ml,10ml and 20ml) Braun/ BD Bioscience 
Syringes Plastipak™ (50ml) BD Bioscience 
Test tubes Cellstar® (15ml and 50ml) Greiner 
Whatman® chromatography paper (3mm) Biometra 
 
3.1.2. Chemicals and reagents 
Table 3.3. List of chemicals and reagents used  
Chemical Manufacturer Storage Usage 
Agar Carl Roth Room 
Temp. (RT) 
LB growth medium 
Agarose 
Seakem® LE  




PAA 2-8°C Cell culture growth medium 
Dimethyl sulfoxide 
(DMSO) 
Carl Roth -20°C Dissolving of compounds and 
control substance; freezing medium 
Fetal calf serum (FCS)  Biochrom -20°C Additive to the cell culture medium 
Peptone-casein Roth RT LB growth medium 
TurboFect™ 
Transfection reagent  
Thermo 
Scientific 
2-8°C Transfecting eukaryotic cells 
Yeast extract Roth RT LB growth medium 
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   Table 3.4. List of other chemicals and reagents 
Chemical Manufacturer Storage Usage 
Ammonium persulfate (APS) Serva RT Polyacrylamide gel 
β-mercaptoethanol Roth 2-8°C SDS sample buffer 
Bromphenolblue Merck RT SDS sample buffer 
Calcium chloride (CaCl2) Roth RT Production of 
competent cells 




RT Tankblot Buffer 
Ethylenediaminetetraacetic 
acid (EDTA) 
Roth RT TE buffer 
Ethylene glycol tetraacetic 
acid (EGTA) 
Serva RT Lysis Buffer A 
Glycerol Roth RT SDS sample buffer 
Glycin Roth RT SDS running buffer 
and Tankblot buffer 
Potassium chloride (KCl) Merck RT Lysis Buffer A 
Potassium phosphate tribasic 
(K3PO4) 
Sigma RT PPBT lysis buffer 
Luminol Roth RT Enhanced 
chemiluminescence 
solution (ECL) 
MgCl2 x 4 H2O Roth RT Lysis Buffer A 
Manganese (II) chloride 
(MnCl2) 
Roth RT Production of 
competent cells 
Methanol Roth RT Cell fixation 
3-(N-morpholino) 
propanesulfonic acid  
(MOPS) 






Roth 2-8°C Polyacrylamide gel 
electrophoresis and 
wash buffer for 
various assays. 
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Potassium acetate Roth RT Production of 
competent cells 
Potassium chloride (KCl) Merck RT Production of 
competent cells 
Rotiphorese® 40 Roth 2-8°C Polyacrylamide gel 
Sodium chloride (NaCl) Roth RT Buffers 
Sodium dodecyl sulfate 
(SDS) 
Roth RT Ingredient in the 
some buffers 
Sodium fluoride (NaF) VEB 
Fluorwerke 
Dohna 
RT Lysis Buffer A 
Sodium orthovandate 
(Na3VO4) 
Sigma RT Lysis Buffer A 
Na2MbO4 Sigma RT Lysis Buffer A 
Tetramethylethylenediamine 
(TEMED) 
Roth 2-8°C Polyacrylamide gel 
Tris(hydroxymethyl)-
aminomethane (Tris) 
Roth RT Ingredient in some 
buffers 
Triton X-100 Merck RT PPBT lysis buffer 
 
3.1.3. Buffers/solutions 
   Table 3.5: List of commercial buffers 
Buffers Manufacturer Storage Usage 
Dulbecco’s 
Phosphate Buffered 
Saline (PBS) with 
Ca & Mg 
PAA 4°C Washing adherent cells and maintaining 
their normal osmotic pressure 
Detection solution 
ECL I + ECL II (1:1) 
Roche 4°C WB detection 
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Table 3.6: List of self-made buffers 
Buffers Content Storage Usage 
SDS running buffer 25mM Tris,19.2mM Glycin, 
0.01% (w/v) SDS 
RT Running of SDS-
PAGE 
Tris-buffered saline + 
Tween 20 
(TBS-T buffer) 
50 mM Tris 
150 mM NaCl 
0.1% (v/v) Tween 20 
RT Blocking and 
washing the PVDF 
membrane; dilution 








2-8°C Cell lysis 
Solution 1 Luciferase 
assay (pH 7.8) 
200 mM Tris-HCl 
15 mM MgSO4 
100 μM EDTA 
1M ATP 
25 mM DTT 
200 μM Coenzym A 
200 μM D-Luciferin 
-80°C Detection substrate 
in reporter gene 
assay 
Standard transformation 





15% (v/v) Glycerin 
2-8°C Production of 
competent cells  
Standard transformation 
buffer (TFB II) 
10 mM MOPS 
NaOH (pH 7) 
75 mM CaCl2 
10 mM KCl 
15% (v/v) Glycerin 
2-8°C Production of 
competent cells 
0.1x Tris-EDTA buffer 
(TE buffer) 
10 mM Tris pH 8 
0.1 mM EDTA 
RT Dilution and 
preservation of  
DNA plasmids 
LB medium 1% Peptone-casein 
0.5% Yeast extract 
85.6 mM NaCl, 7.5 pH 
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LB agar 1% Peptone-casein 
0.5% Yeast extract 
85.6 mM NaCl 
1.5% Agar 
RT Growth medium for 
bacterial cultures 




2.5 mM Tris, 19.2 mM glycine, 
3.5 mM SDS 
RT Electrophoresis 
Haematoxylin 0.5 g Haematoxylin, 
0.1 g NaI, 
25 g KOH solution, 
25 g chloral hydrate, 
0.5 g citric acid in 
500 ml H2O 
RT Staining dye 
(4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid (HEPES)                    
10 mM HEPES, 145 mM 
NaCl, 5 mM KCl, 1mM 
MgSO4,10 mM D-Glucose 
RT Staining procedure 
Loading-buffer (6x) 1.3 mM bromophenol blue,1.6 
mM xylene cyanol,60 % 
Glycerol (v/v), 60 mM EDTA 
RT (in use)  






680 mM NaCl, 13.5 mM KCl, 
 9 mM KH2PO4,  
50 mM Na2HPO4 x 12 H2O, 
pH 7.4 
RT Buffer (washing) 
Ponceau-S-Mix 1 % Ponceau S (w/v), 0.1 M 
trichloroacetic acid, 1.3 M 
sulfosalicylic acid 
RT Staining and 
visualization of 
proteins on WB 
membrane 
Sample buffer (5x) 0.3 mM bromophenol blue,  
500 mg SDS,  
2 ml H2O,  
1.5 ml 
1 M Tris/HCl pH 6.8,  
1.5 ml glycerol,  
550 μl mercaptoethanol 
 
-20°C  Denaturation and 
Staining of protein 
samples 
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Strip buffer 60 mM Tris/HCl pH 6.7, 2 % 
SDS (w/v), 0.4 % 2 ß- 
mercaptoethanol 
RT Western blot 
antibody stripping 
Tris, Acetic acid EDTA 
(TAE) buffer (50x)  
2 M Tris/HCl pH 8.0, 50 mM 
EDTA, 5.7% acetic acid (v/v) 
RT  Agarose gel 
electrophoresis 
Transfer buffer 25 mM Tris/HCl pH 7.5,  
190 mM glycine, 20 % 
methanol(v/v) 




Trypan buffer solution 4 % trypan blue in PBS RT Cell counting stain 
PBST 680 mM NaCl, 13.5 mM KCl,    
9 mM KH2PO4, 50 mM 
Na2HPO4.12 H2O, pH 7.4 
0.05 % Tween 20 
RT Washing  
Developer 12 gm of Na2CO3 (w/v), 80 μl 
0.1% of NaS2O3 x 5H2O (0.1 
gm in 100 ml) 
100 μl formalin, 200 ml dd 
H2O 
RT Silver Gel 
Fixer 100 ml methanol (v/v), 24 ml 
acetic acid,100 μl formalin, 




Silver nitrate  100 mg AgNO3,  
50 ml ddH2O, 








0.25% Coomassie; 45%  
Methanol(v/v), 45% H2O (v/v), 
10% Essigsäure (v/v) 
RT Staining proteins 
on gel 
Separating gel buffer 2.5 M Tris/HCl, pH 8.0 4°C Western blot 
Stacking gel buffer 620 mM Tris/HCl, pH 6.8 4°C Western blot 
Lysis buffer 40 mM Tris/HCl, 
100 mM NaCl, pH 8.0 
4°C Protein production 
Elution buffer 20 mM Tris/HCl,  
20 mM Maltose, pH 8.0 
4°C Protein production 
 
 











Trypsin-EDTA PAA 1x 4°C Facilitates detachment of 
cells from the bottom of 





BamH1, Xho1   





Fermentas 10x -20°C  Cloning 
T4 DNA ligase, 
buffer solution for 
T4 DNA ligase 
Fermentas 1x -20°C Cloning 
Taq polymerase Fermentas 1x -20°C PCR 




   Table 3.8. List of antibiotics 
Antibiotic Manufacturer Stock concentration Storage Usage 
Penicillin/ 
Streptomycin 
PAA 100x -20°C Additive to the cell 
culture medium, prevents 
fungal and bacterial 
contamination 




30000U/ml(50mg/ml)  2-8°C Selection pressure agent 
Ampicillin Carl Roth 1 mg/ml -20°C Selection pressure agent  
Zeocin Invitrogen 1 mg/ml -20°C Selection pressure agent 
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3.1.6. Kits  
 
   Table 3.9: List of commercial kits 
Kit Manufacturer Storage Usage 
Plasmid DNA purification Macherey-
Nagel 
RT Isolation and 
purification of plasmid 
DNA 
Agarose DNA extraction Macherey-
Nagel 
RT Isolation and 
purification of total RNA 
CloneJET
TM PCR Cloning Kit Fermentas -20ºC pJET1.2 cloning system 
5-Prime MasterMix 
 
Fermentas -20ºC Used in PCR 
Phusion® Hot Start High-
Fidelity Polymerase 




All the antibodies were stored at 4ºC. Lab made antibodies were preserved with 0.1% sodium azide 
and all unlabelled stocks were frozen at -20ºC. 
Table 3.10: List of antibodies 
 






Santa Cruz  Goat 1:10000 
Anti-P5D4 P5D4 Lab made Mouse 1 μg/ml 
Anti-His His Tag Qiagen Mouse 1 μg/ml 
Anti mouse CD11c+ PE CD11c+ BD Rat 0.1 μg/ml 
Anti mouse CD86 FITC CD86 BD Rat 0.1 μg/ml 
Anti mouse CD80 FITC  CD80 BD Rat 0.1 μg/ml 
Anti mouse OX 40 PE OX40 Ebiosciences Hamster 0.1 μg/ml 
Anti MBP MBP Lab made Mouse  0.5 μg/ml 
Goat anti rat IgG-PE Rat IgG Santa Cruz Goat 0.4 μg/ml 
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3.1.8. Eukaryotic cells/Cell lines 
a. Primary cells 
 
Table 3.11. List of primary cell 
Cells Bone marrow derived dendritic cells (BMDC) 
Source Isolated from thigh bone marrow of C57BL/6mice 
Splitting  3 days 
Medium 
RPMI with L-Glutamine, 10% of FCS,                                     
1% Penicillin/Streptomycin, 20 ng/ml m GM-CSF 
Description 
Mouse bone marrow derived dendritic cells (BMDCs) are 
obtained from femur of freshly sacrificed mice (BALB/c or 
C57BL/6J) (see method 3.3.1. for details). These are spherical 
adherent cells initially at time of seeding on day 0 but change 
morphology to show dendrites within a week. 
 
b. Cell Lines 
All the cells were grown at 37 ºC at 5% CO2 under aseptic conditions. 
Table 3.12. List of eukaryotic cell lines 
 
Cell line  
Source 







α- MEM, with L-
Glutamine, 10% of FCS, 
1% 
Penicillin/streptomycin 
Spindle shaped adherent 
mouse skin epithelial 
carcinoma cell line. It secretes 
mTSLP on stimulation.  




10% of FCS, 
50μg/ml Gentamycin, 
20 ng/ml of mIL-3 
 
Spheroid shaped, murine IL -3 
dependent pro- B cell line 
established from the bone 
marrow of BALB/c mouse. 
(Palacios & Steinmetz, 1985). 
Grow in suspension culture 
with a doubling time of about 
20 h. 












10% of FCS, 
1% Gentamycin, 
hTSLP 20ng/ml 
Stable cell line made in the lab 
dependent on mIL-3 but 
responsive to hTSLP & hIL-4 















10% of FCS 
1% Penicillin 
Streptomycin 
Zeocin 100 μg/ml 
HEK293T are spindle shaped 
adherent human embryonic 
kidney cell line with sheared 
adenovirus 5 DNA. The cells 
were transfected with a 
plasmid expressing stable 
soluble exo-mTSLPR domain 
to make a stable soluble 
protein secreting cell line.  
 
3.1.9. Bacterial strains  
 
Table 3.13. List of bacterial strains 
Bacterial 
strain  
Source  Medium Genotype Usage 
E. coli- strain 
Top 10 
 









rpsL(StrR) endA1 λ- 
Cloning and plasmid 
amplification  








F– ompT gal dcm 
lon hsdSB(rB- mB-) 
λ(DE3 [lacI 
lacUV5-T7 gene 1 
ind1 sam7 nin5]) 
Used as an expression 
















Fig.3.1. Plasmid map of the vector pcDNA3.1 (+) Neo. The vector is derived from Invitrogen and is suitable for the 
expression of recombinant proteins in eukaryotic system (Product information from Invitrogen).  
This plasmid is suitable for transient and stable expression of recombinant proteins in eukaryotic 
cells. CMV promoter can lead to very high expression levels of the target protein (Boshart et al., 
1985). The bovine growth hormone (BGH) polyadenylation signal is responsible for efficient 
termination of transcription and for polyadenylation of the mRNA. This signal is located behind a 
polylinker in which the cDNA to be expressed can be inserted (Goodwin et al., 1992). The Simian 
virus 40 (SV-40) origin in cells expresses the large T antigen and causes the replication of the vector 
in order to maintain a high plasmid copy number in the proliferating cells (Gluzman, 1981). 
Ampicillin and G418 resistance genes offer the possibility of selection in bacteria or animal cells. 
Table 3.14. pcDNA3.1 + (Neo/Zeo) -derived receptor expression constructs (see Appendix for maps) 
(Wohlmann et al., 2010). 
 
Plasmid  Description 
pcDNA3.1 mTSLPR carrying cDNA of complete murine TSLPR receptor chain, 
G418 resistance and a P5D4 epitope  
pcDNA3.1 mIL-7Rα carrying cDNA of complete murine. IL-7Rα-chain receptor, 
G418-resistance as well as a P5D4 epitope tag 
pcDNA3.1exo-mTSLPR-intra 
hTSLPR Hybrid 
carrying cDNA of exo-murine TSLPRα receptor chain and inner 
hTSLPR chain, G418 resistance and a P5D4 epitope tag  
pcDNA3.1exo-mIL-7Rα-intra 
hIL-7 Rα Hybrid 
carrying cDNA of exo-murine IL7α receptor chain and inner  





carrying cDNA of exo-murine TSLPRα receptor chain, a 
zeocin-resistance as well as hIL-4Rα signal peptide , a TraN 
His8x tag and a P5D4 epitope tag. A version with His6x tag was 
also prepared which had all other components same. 
/zeocin 
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ii) Expression vector pMAL-2 series 
 
 
Fig.3.2 The pMAL-2 vectors expression system for production of mTSLP. pMAL-c2X (6646 base pairs) has its malE 
signal sequence deleted. pMAL-p2X (6721 bp) includes the malE signal sequence. The arrows indicate the transcription 
direction of the gene (product information from New England Biolabs). 
  Table 3.15. pMAL-c2X derived expression constructs (see Appendix for maps) 
Plasmid  Description 
pMAL-c2X Empty vector to produce MBP 
pMAL-c2X-mTSLP-MBP(wild type) carrying cDNA of the fusion protein mTSLP-
MBP(wild type) 
pMAL-c2X-I37EmTSLP-MBP (mutant) carrying cDNA of the fusion protein I37E 
mTSLP-MBP (mutant)  
 
This method produces a high level of expression of the cloned gene sequence by using the strong 
“tac” promoter and the malE translation initiation signals, combining it with a one-step purification 
of the fusion protein using MBP’s affinity for amylose The vectors can express the malE gene (with 
or without its signal sequence) fused to the lacZα gene. The restriction sites in between malE and 
lacZα are available for insertion of the coding sequence of interest.  
In the pMAL-c2X vector, the malE gene on these vectors has a deletion of the signal sequence, 
leading to cytoplasmic expression of the fusion protein. The advantage of the c2X vector is that it 
generally expresses more fusion protein than the pMAL-p2X series. The fusion proteins that cannot 
be exported to the periplasm are more stable in pMAL-c2X vectors.The lacIq gene present in both 
the vectors codes for the Lac repressor. This gene minimizes the Ptac expression low in the absence 
of IPTG induction. The pMAL-2 series vectors also have specifically coded recognitions site for a 
specific protease, located just 5´ to the polylinker insertion sites. This allows MBP to be cleaved from 
the protein of interest after purification.The pMAL-c2X and pMAL-p2X vectors that are used for the 
production of mTSLP encode the site for Factor Xa (Ile-Glu-Gly-Arg). Factor Xa cleaves after these 
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four amino acid recognition sequence so as to leave few or no vector-derived residues attached to the 
protein of interest. This is dependent on the cloning site used for the purpose.The pMAL-2 vectors 
also include the origin of DNA replication site of the E. coli bacteriophage M13, which allows the 
production of single-stranded DNA by infection of cells bearing a pMAL-2 plasmid with a helper 
phage. 
iii) Reporter gene plasmid pGL3-basic 
The reporter gene pGL3-basic is derived from Promega and offers the possibility for quantitative 
analysis of eukaryotic factors regulating gene expression. These include promoters and transcription 
factors. They are encoded with the gene for plasmid firefly luciferase (Photinus pyralis) whose 
expression occurs upon active binding of transcription factors to the promoter region of the reporter 
gene. The receptor specific cell ligand/stimulus thus leads to activation of transcription factors in cell 
signaling, which could thus be quantified as a measure of transcriptional activity in the eukaryotic 
cells. 
 
Fig.3.3 Plasmid map of the vector pGL3-basic. The vector is well suited for quantifying transcriptional activity of 
promoter sequences in eukaryotic cells (product information from Promega). 
   Table 3.16. pGL3-basic derived expression constructs (see Appendix.) 
 
Plasmid Description 
pGL3-basic IRF Luc  
 
Contains the human IRF STAT1 promoter, which serves as a 
sensitive readout of the cytokine response by pSTAT1 activation 
and binding and further transcription of the luciferase gene. 
 
iv) pEGFP 
pEGFP containing the cDNA of eGFP (enhanced green fluorescent protein), a CMV promoter and is 
from the company "Clontech" (Cormack et al., 1996). 
 
 3. Materials and Methods 
31 
 
3.1.11. Oligonucleotides  
 
All oligonucleotides were synthesized by the company Eurofins. 
 
   Table 3.17. Oligonucleotide sequence 
Name Sequence 5´- 3´ 
exo-mTSLPR-TraN-8x His For 
(Forward) 
GCCGGGTCCACTCGAGGCGGCGGCGGTGACGTC 
exo-mTSLPR-His 6x For GGTACCGAGCTCGGATCCATGGCATGGGCACTC
G 
exo-mTSLPR- Rev (Reverse) GATCCAGATGCGGCCGCGAGGGGCGGGGCCAGG
GCCG 
mTSLP-MBP For (p2X) TTTCAGAATTCTACAACTTTTCTAACTGC 
mTSLP-MBP Rev (p2x) GTGCCAAGCTTATTCTGGAGATTGCATGAAGG 
I37E mTSLP-MBP For (c2X/p2X) ATTCAGGAATTCTACAACTTTTCTAACCTGCAAC
TTCACGTCAATTACGAAAATATATTGTAACGAA
AATTTTTCATGACC 
I37E mTSLP-MBP Rev (c2x) CTAGAGGATCCTTATTCTGGAGATTGCATGA 
I37E mTSLP-MBP Rev (p2x) GTGCCAAGCTTATTCTGGAGATTGCATGAAGG 
exo-mIL-7Rα-hybrid For GGTCCAGCGGCCGCGGAAAGTGGAAATGCCCAG
G 
exo-mIL-7Rα-hybrid Rev ATAGGCTCGAGATCCCATCCTCCTTGATTC 
exo-mTSLPR-hybrid For GTCCAGCGGCCGCGGCGGCGGCGGTGACG 
exo-mTSLPR-hybrid Rev ATAGGCTCGAGGAGGGGCGGGGCCAGGGCC 
Oligonucleotides for the mycoplasma test 
Myc For AGCAAACAGGATTAGATACC 
Myc Rev CATCTGTCACTCTGTTAACCT 
 
3.1.12. Cytokine and factors 
 
   Table 3.18. Cytokines and factors used 
Cytokine Company 
mTSLP   R&D Systems GmbH 
mTSLP-MBP Lab made 
mI37E mTSLP-MBP Lab made 
mIL-3 Immunotools 
mGMCSF  Immunotools  





   Table 3.19. Software 
Name Company 
Graphpad prism GraphPad Software, Inc. 
Flowjo Flowjo LLC 
ApE Plasmid editor M. Wayne Davis 
Cyflogic  CyFlo Ltd. 
Microsoft Office Microsoft 
Paint Microsoft 
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3.2. Molecular biological methods 
3.2.1. Preparation of competent E. coli Top 10/ BL-21 DE3 cells  
 
A modified version of the protocol from Hanahan (Hanahan, 1983) for the preparation of competent 
E. coli cells was used. Top10/ BL-21 DE3 cells were grown in 5 ml LB medium overnight at 37°C,  5 
% CO2 and 95 % humidity. Of these 10 μl pre-culture was used to inoculate 200 ml LB medium and 
then shaken up to an OD600 of 0.15-0.3 at 37°C in 1 litre shaker incubation flasks. Subsequently, the 
cells were harvested. All work had to be done on ice maintaining sterile conditions. These solutions 
and equipment were pre-cooled. The culture was divided into tubes (50 ml) and centrifuged for 5 min 
at 4000 rpm, the supernatant was discarded. The pellet was resuspended in 20 ml of transformation 
buffer TFB I, and incubated for 30 min on ice. After another centrifugation for 4 min at 4000 rpm, the 
pellet was taken up in ice cold 4 ml TFB II and mixed well. The batch was then aliquoted into 
Eppendorf tubes to make 30 μl aliquots and snap frozen in liquid nitrogen.The cells were stored at -80 
° C until further use. (For components of TFB see 3.1.3 Table 6). 
3.2.2. Chemical transformation and plasmid amplification in E. coli 
 
For the amplification of plasmids one aliquot of 30 μl of the prepared competent Top10 strains were 
thawed on ice. 50-100 ng of DNA to be amplified was added to the cells. The cells were first 
conditioned for 20 min on ice, and were then heat shocked at 42°C for 90 s after which they were 
immediately put back on ice. Then 1000 μl of LB medium was added and the samples were shaken 
for 30-45 min in the incubator at 37°C and 180 rpm. During this period, the transformed cells should 
express the ampicillin resistance gene. The cells were spun down at 4000 rpm for 5 min. Thereafter, 
40 μl of a mixture was evenly distributed an LB-ampicillin agar plate by a sterile L shaped glass 
spreader and incubated at 37°C overnight. Only the transformed cells formed colonies which were 
visible the next day. From the several colonies a single colony was picked up and used to inoculate a 
200 ml suspension culture with appropriate antibiotic resistance (Ampicillin). This culture was then 
shaken overnight at 37°C until an OD600 of 2-3 was reached. Subsequently, the plasmids from E. coli 
were isolated.   
3.2.3. Isolation and purification of plasmid DNA from E. coli  
 
The purification of the plasmid DNA was  achieved from E.coli cultures by using commercial 
kits, based on the amount of DNA requierd. For small bacterial cultures, the plasmids were isolated 
with Miniprep DNA kit (Machery and Nagel) and for larger DNA yield the NucleoBond® Extra 
Midi (Machery-Nagel) kit was used according to the appropriate protocol for large scale plasmid 
isolation. For longer use, plasmids are stored at -20ºC dissolved in TE buffer or water. 
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3.2.4. Measurement of DNA concentration  
 
The DNA concentration was measured as absorbance on Nano Drop at 280 nm wavelength by using 
2 μl of the DNA sample and a similar amount of water as blank. 
3.2.5. Restriction digestion of plasmid DNA  
 
The DNA digestion with restriction enzymes was always carried out using the series FastDigest® 
(Fermentas Life Sciences) according to the manufacturer's protocol. For analytical approaches, DNA 
constructs always contained 0.5 μg of DNA digested for 15 min. The preparative approaches leading 
to the production of new DNA constructs always contained 3 μg of DNA digested for 1 hr.The insert 
was excised out of the plasmid by incubation with fast digestion enzymes for 1 hr at 37°C as follows:  
 
   Table 3.20. Components of a plasmid digestion reaction 
Ingredients  Volume in μl 
ddH2O add to reach 20 
Plasmid DNA 1 μg 
Restriction enzymes (e.g.EcoR I,  
Hind III) 
each 1 
Restricition buffer (10x FD green buffer) 2  
Total 20 μl 
 
The PCR product was also treated with the restriction enzymes for cleaving off blunt ends for 1 hr at 
37°C. 
3.2.6. Agarose gel electrophoresis 
 
For the agarose gel electrophoresis, the corresponding amount of agarose was dissolved (as the 
percentage of required gel) in 1 x TAE buffer by heating in a microwave followed by cooling to about 
50°C. Red-safe was added in a ratio of 1: 40000. The gel was casted by pouring the mixture into an 
electrophoresis chamber. After polymerization of the gel, the chamber was filled with 1X TAE buffer. 
About 0.5 μg of the DNA to be analyzed was mixed with the loading buffer (6x) and pipetted into the 
wells of the gel. The gel was run for about 20-30 min under a voltage of 100 V. The bands on the gel 
were then viewed as compared to a molecular weight marker, the desired fragments were identified 
and documented in a transillumination UV light chamber (analyzer VWR) or cut out on a UV light 
plate.  
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3.2.7. DNA extraction from agarose gels 
 
The extraction of DNA from agarose gels was mainly used for PCR products and digested plasmids, 
which should be used later for the cloning of novel DNA constructs. After the DNA was 
electrophoretically isolated, 80% of the gel bands were cut out vertically, and put aside. The remaining 
gel was observed under ultraviolet light and target bands marked with a scalpel. Thereafter, the excised 
gel bands were loaded again, and the target product can be isolated without the use of UV light on the 
basis of the markings. The extraction of the DNA was then carried out with a gel extraction kit 
(Machery and Nagel). 
3.2.8. Ligation 
 
100 ng of restricted plasmid and 350 ng of restricted insert DNA were mixed with 1 U of T4 ligase in 
a buffered reaction volume of 20 μl. The mixture was incubated at RT for 1 hr or overnight at 4°C for 
ligation and then transformed into E. coli. 
3.2.9. DNA Sequencing 
 
In order to verify a successful progess of cloning process, the plasmid DNA was sequenced. Cloned 
constructs were sent to either GATC Biotech or Eurofins MWG Operon to be sequenced by modified 
chain termination method. The sequences were analysed by ApE software. 
3.2.10. Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (Saiki et al., 1985) is a molecular biological method used to amplify a 
particular DNA sequence. PCR relies on primer- dependent DNA polymerase replication of a double 
stranded DNA template and depends on an order of distinct steps, which make up a so called cycle of 
reaction. These different steps are performed by a thermocycler. The principle of this method and the 
reaction components are illustrated in the following tables. Denaturation to elongation comprised of a 
cycle and was repeated approximately 25 times for DNA inserts cloned in this project. 
 
   Table 3.21. Principle of PCR                                                              (*Steps repeated during the PCR cycle) 
PCR steps   Description  
Initialisation step (98°C for 10 min Heat activation of polymerases  
Denaturation* (96°C for 30 s) Separation of DNA strands by H-bonds disruption 
Annealing* (for 30 s, primer 
dependent) 
Attachment of primer to DNA strand  
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Elongation*(72°C for 45 s) Synthesis of new complementary DNA srand 
by DNA polymerase (polymerase speed 
dependent) 
Final elongation (72°C for 7 min) Extension of any remaining single-stranded DNA  
      Table 3.22. Reaction mixture 
Component Quantity Component Quantity 
cDNA template 1 μl DMSO 20 μl 
Primer fwd 1 μl ddH2O 1 μl 
Primer rev 6 μl Phusion polymerase 0.25 μl 
Buffer GC 1 μl Total                                   30.75 μl 
dNTPs 0.5 μl 
 
In this thesis, this method was used to generate DNA sequences out of cDNA, generate new restriction 
sites, and introduce point mutations in a DNA sequence. PCR site directed mutagenesis creates a 
defined site in a DNA molecule by using primers that contain the desired mutation. The site next to 
the recognition site for restriction enzyme was the target for site-directed mutagenesis. This was 
accomplished by using mutagenic primers (with non-matching bases) with flanking primers ends to 
generate intermediate PCR products that are overlapping fragments of the entire product. Intermediate 
products are used as template DNA for the second cycle of PCR; strands of each product hybridize at 
their overlapping, complementary regions that also contain the desired mutation. Amplification of 
mutated product in second PCR cycle is driven by flanking primers. The final product possesses the 
desired mutation and can be inserted into an expression vector to generate larger quantities of DNA, 
which need to be sequenced to ensure the presence of the desired mutation. Analytical PCR was also 
used for screening transformed cells. After the transformation of the ligation products the resulting 
colonies were grown in a 24 well plate till an OD600 of 1 and 0.2 μl from it was examined by a PCR 
using specific primers. PCR was performed using a 5-Prime ready mix containing Taq DNA 
polymerase. The corresponding PCR protocol was carried out according to manufacturer's instructions. 
As negative and positive controls were PCR reactions without DNA or a DNA template that contained 
the corresponding nucleotide sequence of the insert. The positive transformed cells produced a band 
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3.3. Cellular biological methods 
3.3.1. Cell culturing and passaging 
 
The cultivation of all primary cells and cell lines was carried out under sterile condition in an incubator 
at 37°C, 95% humidity and 5% CO2.Cell line passages and transfers were performed cultivation was 
performed under sterile conditions in a tissue culture hood. 
 
The cultivation of Ba/F3 cells (non adherent), KCMH-1 and HEK293T (adherent) cells was initiated 
in 25 cm2 flask from frozen cells and is up-scaled to be normally carried out in 75cm2 cell culture 
flasks with the characteristic medium (see Table 3.12 subsection 3.1.8). The dendritic cells (non 
adherent) were cultured in a petri dish. At 90% confluence; the cells adherent cells were split.  
 
In case of adherent cells, after washing the cells with PBS, 2-3 ml Trypsin /EDTA (0.05%/0.02%, 
w/v) was added for 3-5 min in an incubator and then cells detached by knocking on the sides of the 
flask. The HEK293T cells could be also detached directly by tapping without the use of Trypsin/ 
EDTA. The action of trypsin was stopped by the addition of media containing 10 % FCS. After 
centrifugation of the detached cells at 300g for 5 min, the culture flask was seeded with 
approximately 0.5 x 106 cells. In case of the experiments, only 10 cell passages were used for the 
adherent cell lines. The cultivation of the Ba/F3, Ba/F3-mTSLPR cells was carried out in RFG 
medium supplemented with 20 ng/ml mIL-3 or 5% mIL-3 culture supernatant and 10ng/ml rmTSLP 
respectively as growth factors. A cell density of 1 x 106 cells/ml was maintained and cells were split 
in the ratio 1:5 of cell: medium, during passage. For experiments, not more than 25 passages were 
made. The primary dendritic cells survived only for 4-5 days of culturing and were supplemented 
with GM-CSF to support growth and proliferations. 
 
Mouse Bone marrow cells (BMCs) are obtained from femur of freshly sacrificed mice (BALB/c or 
C57BL/6J) (see Fig.3.4) (Madaan et al., 2014). These are round in shape and behave like suspension 
cells at time of seeding on day 0 and are transformed in the presence of GM-CSF to dendritic cells 
displaying extracellular processes on day 6 when they are harvested. The transformation was 
confirmed by testing the expression of CD11c surface marker on the surface of the dendritic cell 
surface using FACS analysis. (see subsection 4.4.2, Fig. 4.2.9) .The medium was replaced on day 3 
and comprised of RPMI 1640, 10% FCS (v/v), 1% Penicillin/Streptomycin and 20 ng/ml of GM-CSF. 




a.       b. 
c.  
d.  
Fig. 3.4. Steps involved in the generation of the dendritic cells from the bone marrow cells from C57BL/6J mice.     a.1-
18 shows the isolation of femur bone from the C57BL/6J mice. b. 16-24 show isolation of cells from the femur by passing 
medium though the bone shaft by a needle.c.25-29 show the seeding of the cells and addition of GMCSF in pic 29 on day 
0.(Madaan et al., 2014). 
The cells were used for migratory studies and surface marker studies.  
3.3.2. Cryopreservation and thawing of cells 
 
To store the cells, they needed to be cryopreserved. Approximately 6 ml (2x106 cells/ml) from a 
cell line with low passages and confluence  between 80-90% was taken. The cells were washed 
with 10 ml PBS and detached by incubation in 3 ml trypsin-EDTA mixture at 37°C. The action of 
trypsin was stopped by an addition of 5 ml medium. The entire suspension was then centrifuged at 
1000 rpm for 5 min and supernatant discarded. The pellet was re-suspended in a mixture of 
70% medium, 10% FCS and 10% DMSO and the cell suspension stored at 80°C in a cryovial 
for a short time prior to the storage in liquid nitrogen.The cryopreserved cells stored in liquid 
nitrogen (-196°C) were thawed by warming in a water bath at 37°C. Subsequently, cells were washed 
to remove the DMSO and then transferred to a 25 cm2 flask with 6 ml media (10% FCS). After 3-4 
days, cells could be passaged into a 75 cm2 flask depending on the state of growth and cells counted. 
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3.3.3. Cell counting 
 
The various assays like the Luciferase reporter gene mono assay required a defined amount of cells. 
Cell concentration was determined by the Neubauer-counting chamber. Cells pellet were suspended 
in 1 ml PBS. A defined volume of this cell suspension was mixed with trypan blue, which stains 
only dead cells. The trypan blue/cell mix was pipetted at the edge of the cover-slip of the Neubauer-
counting chamber. Using a microscope, all cells in 4 large squares of the grid were counted. The final 
number of cells was calculated as: Cell count (as 104 /ml) = Dilution factor x Average count of four 
chambers. 
3.3.4. Extraction of mIL-3-containing supernatants 
 
The untransfected Ba/F3 cells required a constant growth factor dependence of mIL -3. mIL -3 was 
produced by the cultivation of the cell line X63Ag8-653BPV-mIL-3 in (RPMI-1640, FCS and 
gentamycin) RFG medium and was secreted into the supernatant. The cells were cultured at a cell 
density of 2 x 105/ml and grown for 4 days. Subsequently, the supernatant was removed by 
centrifugation of the cells, sterile filtered and stored at -20°C. 
3.3.5. Cultivation and isolation of hybridomas 
 
The production of the hybridoma cells was done by collaboration partner Dr. Michael Küpper, 
University Hospital Rostock. The rats were immunized with the extracellular domain of mTSLPR 
chain and the fusion of the spleen cells from the immunized rat was performed with a myeloma cell 
line (X-63). From the clonal mixtures, hybridoma cells were selected in HAT medium on 96-well 
plates and grown on RFG medium after about 3 weeks with 20 ng/ml rhIL-6. The clonal mixtures that 
survived were grown in at a cell density of approximately 5x104 cells per well on 24-well plates, and 
further cultured on 6-well plates. Depending on the growth rate, the cells were split every 2-4 days in 
a ratio of 1: 5 and fed with fresh medium. The isolation of clonal mixtures was carried out in a 96-well 
plate. 6x104 cells were seeded in well A1 and then were serially diluted 1:1 vertically from wells B1-
H1. A horizontal dilution in 1: 1.ratio was performed starting from the first well A1 of each horizontal 
row. The clones that showed proliferation were considered and isolated in this way and viewed from 
the bottom right of this separation, only for the first clones. In this way, one could expect to have 
obtained monotype clones. 
The cultivation of the individual monotype clones recovered for the production of supernatants was 
carried out on 6-well plates. In order to obtain large amounts of supernatants the cultivation was carried 
out in 175 cm2 cell culture flasks with RFG-medium and 20 ng/ml rhIL-6. Medium was harvested 
every 3-4 days depending on the growth of the cells and replaced by fresh medium. The cells were 
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split in the ratio of 1:5. The supernatants thus obtained were cleared of the debris by centrifugation at 
1000 rpm for 5 min. The supernatant was frozen at -20°C. 
3.3.6. Mycoplasma test  
 
The cells were screened for mycoplasma infection every 2 weeks.2μl of cell free supernatant were 
checked for possible contamination by a PCR-based Mycoplasma detection kit (Biochrom AG). 
Infected cultures were immediately discarded and destroyed. 
3.3.7. Transfection by electroporation 
 
Electroporation is a mechanical transfection method which allows cellular introduction of large highly 
charged DNA molecules. This method utilises an electric pulse to rearrange the hydrophobic bilayer 
resulting in small pores across the membrane. These pores serve as an entrance for DNA molecules. 
Transient transfection of the HEK293T cells/Ba/F3 was performed using the device Nucleofector®- 
Lonza (Maasho et al., 2004). For this, the cells were detached at reaching 80% confluence by 
trypsinization or by tapping the cell culture flask and and washed with PBS. The cells were starved to 
about 6-8 h (by removing the growth factor mIL-3 in Ba/F3 cells and FCS in HEK cells). 1 x 106 cells 
with 100 μl transfection solution V and 2μg plasmid was added. The transfection was carried out as 
electroporation with the program A-23 for HEK293T cells and T-16 for Ba/F3 cells. The cells were 
then seeded in the corresponding medium (see 3.1.8) in the desired numbers, stimulated or 
unstimulated as design of the experiment and grown in cell culture flasks/plates incubated at 5% CO2 
for 72 h at 37°C. 
3.3.8. Lipofection 
 
Stable transfection of HEK293T cells was carried out with Turbofect® (Lonza) by lipofection. This 
technique utilises liposomes to transfer genetic material into a cell. Liposomes are vesicles that can 
easily merge with cell membranes since they are both made of phospholipid bilayer. Lipofection has 
high efficiency, ease of use, reproducibility, low toxicity and its ability to transfect a wide range of 
cell types. TurboFect™ in vitro transfection reagent is a sterile solution of a proprietary cationic 
polymer in water. The polymer forms compact, stable, positively charged complexes with DNA. 
These protect DNA from degradation and facilitate gene delivery into eukaryotic cells.The complexes 
are endocytosed via lysosomes or endosomes and provoke a massive chloride influx. Due to a rapid 
osmotic swelling, endosomal rupture occurs, allowing a translocation of DNA to the nucleus.Initially, 
250,000 cells per well were seeded into a 12-well-plate and settled at 37°C over night. The next 
day, 2 to 5 μg of plasmid DNA was mixed with 200 μl of appropriate medium and 2 μl of 
TurboFect Reagent, and incubated at room temperature for 20 min. Subsequently the suspension 
was added dropwise to the adherent cells. Transfection results were examined after 24 to 48 h. 
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3.3.9. Luciferase reporter gene assay 
 
Reporter gene assays are widely used to determine eukaryotic gene expression and cellular 
physiology. By using this system receptor activity, transcription factors, intracellular signalling, 
mRNA processing and protein folding can be investigated. In this thesis, luciferase reporter gene assay 
was used to determine the relative upregulation of the cytokine (mTSLP) induced activity by using the 
luciferase reporter gene construct with a promoter responding to a downstream STAT1 transcription 
factor (IRF-1-Luc). For this purpose the ‘Luciferase Assay System’ was used from Promega. The 
monoassays were used in the experiments with transiently transfected Ba/F3 mTSLPR cells. In the 
mono-assay all transfected cells were pooled and divided into identical aliquots and then stimulated 
by cytokine treatment except for the negative control. At the end of each stimulation period, cells were 
lysed for 15 min and the amount of expressed firefly luciferase was measured by adding Luciferase 
assay substrate-I in the luminometer. Here, the luciferin contained in the added buffer coverts to 
oxyluciferin in the cells which expressed luciferase, thus producing a chemiluminiscence signal which 
can be recorded by the luminometer. (Sherf, B.A et al., 1996). 
 
Fig.3.5. A schematic overview of the chemical reactions underlying the Promega Luciferase® Reporter Assay. 
All measurements were carried out in a luminometer GloMax® Promega. This device allows very 
sensitive measurement and the automated pipetting of each buffer in order to obtain consistent and 
comparable values. The following settings were used: sample to be measured per well 25 μl, luciferase 
assay substrate I 30 μl measurement time per well 5 s.The intensity of the luminescence (LU) is 
proportional to the expressed luciferase and so that it allows accurate quantification of the relative 
cytokine activity (Wood et al., 1984). A comparison of the measured intensities from the unstimulated 
cells to that of the cytokine stimulated cells provides a measure of the relative stimulation of a reporter 
gene construct. 
3.3.10. Flow cytometry   
 
Flow cytometry is a method which can be used to analyze various parameters of an individual cell 
in a homogenous or heterogenous population. This technique involves the passage of thousands of 
cells per second across a laser beam. The cells suspended in PBS are sucked and passed through a 
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capillary in the fluidic chamber such that one cell individually moves past a laser beam. The incident 
light is deflected in different directions based upon the size and granularity of the cell. Forward 
scattered light (forward scatter or FSC) provides information on the relative size of the cell, lateral 
scattered light (sideward scatter or SSC) is a measure of the surface quality/granularity of the cell. 
The data gathered can be analyzed statistically by flow cytometry software to report cellular 
characteristics such as size, complexity, phenotype, and health of the cell.  
 
In this thesis, flow cytometry was used to study the expression of receptor chains on the surface 
of Ba/F3 cells and the surface markers on the dendritic cells. The cells were initially washed and 
treated with Fc bockers (IgG) containing PBS if needed for 20 min. The markers were stained by 
using 1 μg of antibodies directed against the target (P5D4 tag in recptor cells and anti-CDs in 
dendritic cells). The cells were incubated for 30-60 min and twice washed with PBS and analysed 
on the cytometer as per the protocol. If a secondary antibody was used then another incubation of 
30 min was given for incubation with secondary antibody. GFP expression was analyzed by direct 
measurement of the cells. For GFP and FITC FL-1 channel was used for detection while FL-2 
channel was used for detection of PE based signals. Data analysis was performed with Cyflogic 
BD FACS diva and Flow Jo data analysis software. 
 
3.3.11. Staining of dendritic cell carrying well-inserts during migration assays 
 
Well-inserts were washed in HEPES and fixed in 4% PFA (ice cold) for 10 min on the outer side. The 
inserts were washed 3 times with distilled water. The inserts were stained in Haematoxylin stain (1 ml 
in a 6 well plate and 0.5 ml in the insert). The inserts were washed 3 times in tap water and kept for 10 
min in warm water so that the water turns blue. The inserts were cleared on the inner surface using 
cotton buds and kept on the plate and left overnight for drying.Next day the membranes were cut and 
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3.4. Protein biochemical methods 
3.4.1. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein separation by SDS-PAGE was used in this thesis to estimate approximate relative molecular 
mass, to determine the relative abundance of major proteins in a sample, and to determine the 
distribution of proteins among fractions obtained during chromatographic separation. This technique 
separates proteins according to their electrophoretic mobility. For this purpose, a polyacrylamide gel 
as a support medium and SDS to denature the proteins are used. SDS is a detergent that induces 
denaturation of the protein and creates negative charge around the polypeptide chain. The negative 
charges on SDS destroy most of the complex structure of proteins and are attracted strongly towards 
the anode in an electric field. The monomers of acrylamide are cross-linked to a polymeric matrix 
and the reaction is initiated by APS (ammonium persulfate), which produces free radicals. TEMED 
(tetramethylethylenediamine) stabilizes the free radicals as a catalyst in this process. The molecular 
mass of the determined protein defines the porosity of the gel used. The bigger the molecular mass 
of a protein, the smaller is the percentage of acrylamide in the separating gel. The following table 
shows composition of reagents used in a 12.5% polyacrylamide gel which was frequently used in 
this thesis. 
   Table 3.23. Composition of 12.5% gels 
Component (for 2 gels) Volume for Seperating gel  Volume for Stacking gel 
Distilled water 2.1 ml 2.0 ml 
Seperating gel buffer  
(2 M Tris HCl) pH 8.0 
2 ml X 
Stacking gel buffer 
(0.5 M Tris HCl) pH 6.8 
X 1.3 ml 
Acrylamide (40%) 3.7 ml 700μl 
Glycerine (40%) 4 ml 1.0 ml 
SDS (20%) 50 μl 25 μl 
APS (10%) 50 μl 40 μl 
TEMED 10 μl 10 μl 
 
During SDS-PAGE electrophoresis, gel assembly was used to create 1 mm thick gels by using 
appropriate seperators (Bio-Rad): The seperating or resolving gel was first poured (about 4/5 of the 
gel height) and covered with isopropanol layer to avoid distortion due to drying of the gel. After 
approximately an hr (polymerization of the separating gel), isopropanol was dried and the stacking 
gel was poured in between the plates and the corresponding combs were inserted depending on the 
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number of samples. Each sample (approx. 15-80 μg protein in 15-20 μl total volume) was added with 
5 μl of 5x protein sample buffer and denatured at 95°C for 5 min. The sample buffer denatures the 
proteins. After filling the electrophoresis chamber of the mini PROTEAN® system from Bio-Rad 
with electrophoresis buffer solution, the prepared samples and a molecular weight marker were 
loaded onto the gel in different lanes as per the loading scheme. The molecular weight marker "Pager 
Ruler Plus" (Fermentas Life Sciences) serves as a size standard. An initial electric field of 100 V and 
0.25 A was used for 20 min until each sample was within the stacking gel. For the separating gel 
electrophoresis, a voltage of 180 V and 0.5 A was used for approximately for 90 min. The proteins 
were thus separated and could be visualized by different staining methods, or can be blotted on a 
membrane using western blot. Coomassie staining was used for the visualization of the proteins 
produced by bacterial cloning in this thesis. The mTSLPR protein production was visualized by silver 
staining and western blotting. 
3.4.2. Coomassie staining 
 
The gels were stained in Coomassie stain for 30 min and then de-stained using de-stainer solution 
(for composition of solution see 3.1.3) .The protein bands were stained in blue color.  
3.4.3. Silver staining 
 
The SDS page gels were incubated in the fixer solution for 60 min. The gels were washed in 50% 
ethanol for 15 min followed by 30% ethanol for another 15 min. The gels were then shaken in sodium 
thiosulphate solution for 1 min and washed 3 times in water quickly within 30 seconds. The gels 
were then incubated in silver nitrate solution for 20 min and then washed 3 times with water. The 
gels were then incubated in developer solution, which was often changed to reduce background. The 
development of the gels was stopped by shaking the gels in 5% acetic acid solution. The gels were 
finally washed for 10 min twice in water to remove the acid. The developer, silver nitrate solution 
and sodium thiosulphate solutions are always prepared fresh for silver staining (For composition of 
solutions, see 3.1.3). 
3.4.4. Western blotting 
 
Western blotting is an analytical technique which allows the detection of specific proteins in a given 
sample. In this technique, after the SDS-PAGE, the proteins which have been separated on the gel 
are transfered from the electrophoresis gel to the membrane, either nitrocellulose or polyvinylidene 
difluoride (PVDF), by applying a lateral electric field across the gel and the membrane. The proteins 
of interest can be detected by using specific antibodies. 
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The western blot was performed in a Bio-Rad Western Blot apparatus. The assembly was organized 
in the order: sponge filter, gel, membrane, filter, sponge. The gel was placed on the cathode side to 
ensure the transfer of the proteins in the right direction. The blot chamber was then filled up with 
transfer solution buffer and protein transferred to a membrane at 0.3 A and 100 V at room temperature 
for 1.5-2 h. Due to their negative charge, proteins in the gel move to the positive pole on to the 
membrane. To check whether the blotting process was successful, the membrane was stained with 
Ponceau S solution. This sodium diazo- dye stains reversibly stains the protein bands red on the 
membranes. The nitrocellulose membrane was incubated for 15 min with Ponceau S solution and 
then rinsed with tap water until the proteins were visible as bands. In this way, it was possible to 
check the protein transfer as well as a uniform protein loading of different tracks.  
The membrane was then blocked with milk protein solution for 1 hr to prevent any non-specific 
antibody binding. Milk powder contains a mixture of proteins, which bind to non-protein areas on 
the membrane, and thus allows specific immunological detection of the target proteins.  
After incubation in milk protein solution the membranes were washed with TBS-T and incubated 
with a primary antibody solution at room temperature for 1 h or at 4°C over night. The primary 
antibody solution comprised of the specific dilution of primary antibody dissolved in 1x TBS, 0.1% 
Tween-20 (v/v); 5% BSA (w/v); 0.02% NaN3 (w/v). BSA was added to the solution in order to block 
non-specific binding and sodium azide as a preservative. After primary antibody incubation, unbound 
antibodies were removed by washing with TBS-T three times. The membrane was then incubated 
with a secondary antibody solution (1 x TBS; 0.1% Tween-20 (v/v), secondary antibody 1:10000) 
for 1 hr. The secondary antibody was coupled to horseradish peroxidase. The choice of species of 
secondary antibody depended on the primary antibody.  
Subsequently, Lumi-light western blot substrate 1 and 2 were mixed 1:1, added to the membrane and 
incubated for 5 min. This solution contains peroxide which is a substrate for horseradish 
peroxidase.This enzyme catalyses the oxidation of luminol to 3-aminophthalate by formation of 
several intermediate products. From this reaction, light is emitted at 428 nm, which then was used 
for detection of the specific protein by chemo-luminescence chamber (analyzer VWR). The 
membrane was then stored at -20 ºC. 
3.4.5. Chromatographic protein purification of His tagged proteins 
 
The histidine tagged receptor exo domain receptor protein purification was performed with the Fast 
protein liquid chromatography (FPLC), Äkta purifier® (GE Healthcare). A FPLC system allows 
automated and consistently reproducible protein purification process. To purify the exo-mTSLPR-
domain 8x-His tagged protein, a 2 ml nickel Sepharose column (GE Healtcare) was used. The 
proteins containing supernatant as obtained from the HEK-exo-mTSLPR-cell line was filtered and 
dialysed overnight in 20 mM sodium phosphate buffer pH 7.5. The supernatants were then pumped 
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over the nickel column and then washed with buffer in next cycle. The bound protein was eluted with 
an increasing step gradient of Imidazole. The eluted fractions were collected in the fraction collector 
and then analysed for the presence of protein using western blotting and silver gel. The 
manufacturer's specifications for flow rate and purification steps of the matrices were followed. Once 
a program has been obtained, it can be used for further purification cycles. The proteins were dialysed 
in a membrane bad in required buffers overnight at 4ºC. 
3.4.6. Expression and purification of MBP-fusion proteins 
a. b.  
Fig.3.6. The pMAL-2 vectors expression system for production of mTSLP. a. pMAL-c2X (6646 base pairs) has its malE 
signal sequence deleted.pMAL-p2X(6721 bp) includes the male signal sequence. The arrows indicate the transcription 
direction of the gene. The unique sites for restriction are shown. b. Scheme showing the cloning and purification steps using 
the pMAL system via affinity chromatography on amylase column. 
The pMAL™-2 vectors (Fig. 3.6) express the target protein quickly and efficiently as a fusion protein 
along with maltose-binding protein (MBP) separated by a cleavage site. The gene of interest 
(mTSLP/I37E mutant mTSLP) was cloned downstream from the malE gene of E. coli, encoding the 
maltose-binding protein (MBP), resulting in the expression of an MBP fusion protein.  
It was decided initially to try the p2X and the c2X series and to choose the better one. In p2X series 
vectors, the protein is produced in the periplasmic space. The signal peptide, on pre-MBP guides the 
fusion proteins the periplasm. If the mTSLP fusion protein could be successfully exported, this would 
allow the folding and disulfide bond formation to successfully take place in the periplasm of E. coli, 
so as to allow the purification of the proteins from the periplasmic space.  
The pMAL-c2X and pMAL-p2X vectors that are used for the production of mTSLP encode the site 
for Factor Xa (Ile-Glu-Gly-Arg). Factor Xa cleaves after these four amino acid recognition sequence 
so as to leave few or no vector-derived residues attached to the protein of interest. This is dependent 
on the cloning site used for the purpose. 
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An overnight culture was produced by growing a colony from the respective plates produced above in 
100 ml of LB medium with glucose (1%) + Ampicillin (1:1000) in two respective conical flasks. 20 
ml of overnight culture was used from each flask to inoculate total 1 litre of respective cultures (LB 
medium with glucose (1%) + Ampicillin (1:1000)) in 2 ml flasks. The bacteria were grown at 190 rpm 
and 37°C for approximately 3 h when an O.D. of 0.5 was reached. At an O.D. of 0.5 cells were induced 
with a molecular mimic of allolactose, a lactose metabolite that triggers transcription of the lac operon, 
1M Isopropyl β-D-1-thiogalactopyranoside (IPTG), before which some uninduced sample was 
collected for Coomassie gel analysis. The flasks were shaken for another 6-8 h at 190 rpm and 37°C 
for production of adequate protein. 
 
Purification by affinity chromatography from the periplasmic extract: The protein laden cells obtained 
above were harvested by spinning on the centrifuge them at 4000 rpm for 20 min. The pelleted bacterial 
cells were resuspended in 400 ml of 30 mM Tris-HCl; 20% sucrose; pH 8.0.  EDTA was added to the 
mixture (0.15 g in 400 ml). The mixture thus obtained is incubated for 5 – 10 min at room temperature 
on a shaker. Now the mixture was centrifuged at 8000x rcf for 20 min at 4°C. All the supernatant was 
removed. The pellet was resuspended in 400 ml of 5 mM MgSO4. The mixture is then incubated on an 
ice bath on a shaker for 10 min. The mixture is again centrifuged at 8000x rcf for 20 min at 4°C. Now 
to the supernatant was added 8 ml of 1 M Tris-HCl; pH 7.4 (osmotic shock fluid). After this 
equilibration of the amylose resin column with Lysis buffer (2x – 3x column volumes) was performed. 
The sample was loaded on the column. The column was washed with 2x – 3x column volumes Lysis 
buffer. The fusion protein was eluted with elution buffer. The eluted fractions were collected as volume 
of 500 μl each (around 5 ml of elution buffer was used so as to produce 10 fractions of eluted solution). 
The protein samples could be dialysed in Dialysis buffer (10 mM Tris-HCl; 50 mM NaCl; pH 8.0).The 
proteins samples were run over a 12.5% SDS gel and a Commassie staining was performed (see 
section.4.3). The concentration of the protein was determined by measuring the concentration on the 
Nanodrop spectrophotometer or a Bradford assay. Prot Param tool was used to get the actual 
concentration by dividing it with the extinction coefficient. For the samples shown in figure the 
concentration of protein was 2.5 mg/ml. Additional bands were seen in Coommassie perhaps point out 
that the protein undergoes degradation or half trancribed protein fractions are produced. 
Purification by affinity chromatography from the cytoplasmic extract: The protein laden cells obtained 
above were harvested by spinning on the centrifuge them at 4000 rpm for 20 min. The cells pellets 
obtained were resuspended in 3 ml of Lysis buffer (protease inhibitors were added). The cells were 
sonicated at 3x 40 cycles. The cells lysate thus obtained was centrifuged at max.speed for 30 min at 
4°C. The amylose resin columns were equilibrated with Lysis buffer (2x – 3x column volumes). The 
supernatant from the centrifuged lysate was loaded on the column. The column was washed with 2x – 
3x column volumes with Lysis buffer. The protein was eluted with the elution buffer. Fractions of 500 
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μl were collected (around 5 ml of elution buffer was used so that means 10 fractions of eluted solution 
were obtained). The protein samples could be dialysed in dialysis buffer (10 mM Tris-HCl; 50 mM 
NaCl; pH 8.0). The proteins samples were run over a 12.5% SDS gel and a Commassie staining was 
performed. The protein concentration was determined by measuring by Nanodrop or doing a Bradford 
assay and dividing it with extinction coefficient calculated from the Prot Param tool online.  
3.4.7. Enzyme-linked immunosorbent assay (ELISA)  
 
The binding activity characterization of the cytokine and their receptors was done by an ELISA. An 
immunoabsorbent 96 well ELISA plate was coated with wild type mTSLP-MBP fusion or 
commercial TSLP for overnight mixed with PBS. The plate was then treated with exo-mTSLPR -
His8x TraN in increasing concentrations (Fig. 4.12,4.13) and the binding quantified by detecting the 
His Tag via anti His primary and HRP conjugated secondary antibodies and 3,3’,5,5’–
Tetramethylbenzidine (TMB)-Citrate Buffer substrate reaction. The reaction was stopped using 2N 
H2SO4 and the absorbance from the plate was read in an ELISA plate reader at measurement 




















4.1. Generation of an effective readout system for characterizing and analyzing 
murine TSLP (mTSLP) signaling activities 
4.1.1. Improvisation of the Ba/F3 system to generate a novel readout system for the 
quantification of the relative bioactivity of murine TSLP (mTSLP)  
 
The cytokine mTSLP activates the cell signaling via the JAK Stat pathway (Wohlmann et al., 2010). 
An artificial system was designed to quantify the activation of the STAT signaling cascade inside 
the cells in the form of a relative readout. This system could be used for comparing the luciferase 
reporter gene activity of mTSLP receptor expressing Ba/F3 cells treated with cytokine to that of the 
cells without any cytokine treatments. The readout system expressing the native chains on the cell 
surface was designed as follows: 
Ba/F3 cells which are murine pro B cells were transfected with the receptor chain expressing 
plasmids: pcDNA3.1 mTSLPR, pcDNA3.1 mIL-7Rα and reporter gene pGL3-basic IRF1 Luc using 
T-16 program on the Amaxa Nucleofactor device (refer protocol in subsection 3.3.7). The transfected 
plasmids expressed chains similar in structure to the native mIL-7Rα and mTSLPR chains in 
approximately 12 h and the activity of the reporter gene was best observed between 16-18 h after 
transfection.  
 
To check the status of the expression of the chains on the surface of the cells, cytometric analysis 
was performed after transfecting 1 million cells with 5μg plasmid of only one DNA receptor chain 
thereby expressing only single chain of the receptor on the surface of the cell. Both the chains 
expressed a tag P5D4 after 12 h of transfection, which could be detected via flow cytometric analysis 
using a primary antibody directed against P5D4 tag and a secondary fluorophore conjugated antibody 
anti mouse IgG-FITC (visible in FL-1 channel) (see Fig. 4.1. a-j). 50000 cells were analysed on 
CyFlogic software. This anti- P5D4 signal readout serves as a direct estimated measure of the 
expression of mIL-7α and TSLPR chains. The overlay plots between empty vector transfected cells 
and cells transfected with vector expressing receptor chains (see Fig 4.1 e), showed a low signal shift 
which indicates that the mIL-7Rα chains were expressed but in a low amount. The mTSLPR chains 
were expressed in moderate amounts (see Fig 4.1 j). 
 





Fig.4.1 Flow cytometric analysis of mIL-7α and mTSLPR receptor chain expression on the surface of the transfected 
Ba/F3 cell line. Anti- P5D4 Tag Ab treated Ba/F3 cells showing the expression level of murine IL-7/TSLPR chain on the 
surface of the Ba/F3 cells. The Ba/F3 cells transfected with the empty vector plasmid pcDNA3.1, pcDNA3.1 mIL-7Rα or 
pcDNA3.1 mTSLPR and then analysed by flow cytometry after staining with the anti- P5D4 tag and a secondary 
fluorophore conjugated anti mouse IgG-FITC antibodies after 12 h. a. cells transfected with empty vector pcDNA 3.1, b. 
Histogram for transfected cells with empty vector pcDNA 3.1, c. cells transfected with vector pcDNA3.1 mIL-7Rα, d. 
Histogram of mIL-7Rα expressing transfected Ba/F3 cells, e. An overlay of the histograms in b and d showing the 
expression levels of the mIL-7Rα chain, f. cells transfected with empty vector pcDNA3.1, g. histogram for transfected cells 
with empty vector pcDNA3.1, h. cells transfected with vector pcDNA3.1 mTSLPR, i. histogram of cells transfected with 
vector pcDNA3.1 mTSLPR, j. An overlay of the histograms in g and i showing the expression levels of the mTSLPR. 
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Further, in order to check whether the receptors expressed on the cell surface are biologically 
functional, a luciferase reporter gene assay was performed. The activity of the transient Ba/F3 
reporter cell line was tested by treating the reporter gene construct pGL3-basic IRF1 Luc transfected 
cells with a series of various dosages of mTSLP. mIL-3 serves as a positive control for the reporter 
gene (see Fig 4.2). 
a.                           b.                   
 
Fig.4.2. Luminometric analysis of the dosage response exhibited by the Ba/F3 luciferase gene readout system.   
a. Ba/F3 cell luciferase reporter gene system setup (see text for details) b. relative luciferase activity readout on 
luminometer. The plasmids for expressing the native chains mTSLPR/IL-7α and IRF Luc reporter gene were transfected 
in the Ba/F3 cells (T-16 Amaxa program). The cells were given various treatments with cytokine mTSLP in ng/ml as 
shown, lysed after 16 h and luciferase gene activity evaluated on a luminometer. mIL-3 (20 ng/ml) serves as a positive 
control for the reporter gene. SD is derived from duplicate samples and shown as error bars. Shown are representative data 
from three independent experiments. 
_______________________________________________________________________________ 
 
The relative luciferase reporter gene readout yielded a low comparative luciferase signal mith 
maximum value as 3 fold. This value of comparative luciferase signal was not sufficient enough for 
sensitive evaluation of ligand activity. The low amplification magnitude factor 3 of the luciferase 
assay readout is in line with the findings of the results obtained from flow cytometry which indicated 
the low expression of the mIL-7Rα receptor chain (see Fig. 4.2.b.).  
4.1.2. Ba/F3 cells system expressing hybrid exo-mouse – intra-human receptor chains 
on cell surface 
 
It has been shown in the previous section 4.1.1 that the readout based on the native receptor chains 
is unsatisfactory. It demanded further improvisation so as to get a better evaluation on the readout 
system. To make this system better we created the exo-mouse – intra-human chain hybrid chains as 
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described in next section. It was observed by Andreas Wohlmann that the hybrid receptors are 
providing better amplification of luciferase signals when used together with human intra domain 
receptor chains (Wohlmann, 2014). Based on this observation it was decided to combine the exo-
domains of mouse into already existing human TSLP receptor chains.The hybrid receptors were 
generated by constructing the expression plasmids pcDNA3.1 exo-mTSLPR-intra-hTSLPR hybrid 
and pcDNA3.1 exo-mIL-7Rα-intra-hIL-7Rα hybrid. These hybrid genes were amplified by 
generating the DNA sequences encoding the murine exo domains by PCR using primers:               1. 
exo-mIL-7Rα-hybrid-For/Rev and 2. exo-mTSLPR-hybrid-For/Rev. These inserts were then ligated 
into the pJET vector. These pJET vectors carrying inserts were then verified by colony PCR followed 
by a sequencing of the positive colony, to confirm the presence of the target insert. These were then 
excised and ligated in the excised plasmids pcDNA3.1 intra-hTSLPR and pcDNA 3.1intra-hIL-7Rα. 
(see Fig. 4.3). Finally pcDNA3.1 exo-mTSLPR-intra-hTSLPR hybrid and pcDNA3.1 exo-mIL-7Rα-
intra-hIL-7Rα hybrid were obtained as a result.  
 
 
Fig.4.3. A schematic representation of cloning performed for generating the hybrid chain expressing plasmids. The 
DNA inserts which express exo-domains of murine TSLP receptor were cloned in already existing hTSLP receptor chain 
expressing plasmid DNA. The cloning was carried out in three steps as shown above. For details see text. 
 4. Results 
53 
 
To evaluate functional properties, 1 million Ba/F3 cells were taken and transfected with 5 microgram 
of the receptor chains expressing plasmids: pcDNA3.1 exo-mTSLPR-intra-hTSLPR hybrid and 
pcDNA3.1 exo-mIL-7Rα-intra-hIL-7Rα hybrid as cloned above and reporter gene pGL3-basic IRF1-
Luc using T-16 program on the Amaxa Nucleofactor device (Refer protocol Nucleofaction (Section 
3). 
 
The transfected plasmids expressed chains exo-mTSLPR-intra-hTSLPR hybrid and pcDNA3.1 exo-
mIL-7Rα-intra-hIL-7Rα hybrid on the surface of the cells in approximately 12 h and the activity of 
the reporter gene was best observed between 16-18 h after transfection. To check the status of the 
expression of the chains on the surface of the cells, flow cytometric analysis was performed after 
transfecting the cells with only one plasmid DNA thereby expressing only single chain of the 
receptor. Both the chains expressed a tag P5D4, which could be detected by using a primary antibody 
directed against P5D4 tag and a secondary fluorophore conjugated antibody anti mouse IgG-FITC 
on FACS after 12 h of transfection (see Fig Results 4.4). This Anti- P5D4 readout serves as a direct 
estimated measure of the expression of mIL-7 and mTSLPR chains.  
The overlay plots showed a stronger signal shift which indicates that the pcDNA3.1 exo-mTSLPR-
intra-hTSLPR hybrid and pcDNA3.1 exo-mIL-7Rα-intra-hIL-7Rα hybrid chains were expressed in 
a higher amount as compared to the wild type native chains as described in 4.1.1. 





Fig.4.4. Flow cytometric analysis of hybrid receptor chain expression on the surface of the transfected Ba/F3 cell 
line. Analysis of exo-mIL-7Rα-intra-hIL-7Rα receptor expression on the surface of the Ba/F3 cell line using flow 
cytometer: a-e. Anti- P5D4 Tag expression readout showing the expression level of the pcDNA3.1 exo-mIL-7Rα-intra-
hIL-7Rα to produce exo-mIL-7Rα-intra-hIL-7Rα chain on the surface of the Ba/F3 cells. The cells were transfected with 
the plasmids and then readout after staining with the anti- P5D4 tag and a secondary flurophore conjugated anti mouse 
IgG-FITC antibodies on FACS after 12 h. a. cells transfected with empty vector b. histogram of cells transfected with 
empty vector c. cells transfected with the plasmid pcDNA3.1 exo-mIL-7Rα-intra-hIL-7Rα d. histogram of cells transfected 
with pcDNA3.1 exo-mIL-7Rα-intra-hIL-7Rα e. overlay of histograms b and d.  
Analysis of hybrid chains pcDNA3.1 exo-mTSLPR-intra-hTSLPR receptor expression on the surface of the Ba/F3 cell line 
using flow cytometer f-j.: Anti- P5D4 Tag expression readout showing the expression level of the exo-mTSLPR-intra-hIL-
7Rα to produce exo-mTSLPR-intra-hIL-7Rα chain on the surface of the Ba/F3 cells. The cells were transfected with the 
plasmid and detected as above 12 h. f. cells transfected with empty vector g. histogram of cells transfected with empty 
vector h. cells transfected with the plasmid pcDNA3.1 exo-mTSLPR-intra-hIL-7Rα i. histogram of cells transfected with 
pcDNA3.1 exo-mTSLPR-intra-hIL-7Rα, j. overlay of histograms b and d. Shown are representative data from three 
independent experiments. 
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A receptor activity control test was performed so as to make sure that the single receptor chains 
transfected in the Ba/F3cells do not give false positive signals with some native receptor present on 
the cell surface. Also the specificity of the transient Ba/F3 readout can be tested by treating the 
system with another cytokine except mTSLP. Here we used hIL-4 (see Fig. 4.5 c.). It was observed 
that there was only a signal when all the three chains were transfected together and treated with 
mTSLP. This indicates that the system is highly specific for induction with mTSLP. 
As already described above for the native receptors, the activity of the transient Ba/F3 reporter cell 
line was further tested in a luciferase reporter gene assay by treating the transfected cells with a 
gradient of various dosages of mTSLP. mIL-3 serves as a positive control for the reporter gene (see 
Fig 4.5 b). 
The receptor chains show improved expression levels. This is improved luciferase reporter gene 
readout as compared to the one described in 4.1.1. This system with hybrid chains yields an improved 
evaluation of the quantified data to the order of 6 fold signals as compared to the untreated sample. 
This is in line with the obtained observations through flow cytometry which show that the hybrid 
chains are expressed well on the surface of the cells. 
a.               b. 









































Fig 4.5. Analysis of signalling activity of the murine 
TSLP hybrid receptor chains with Ba/F3 luciferase 
gene readout system Ba/F3 Luciferase readout with 
hybrid chains b). Ba/F3 cell-hybrid chain luciferase 
reporter gene readout on Glomax. The hybrid chains exo-
mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-
7Rα hybrid and IRF-Luc reporter gene were transfected in 
the Ba/F3 cells (T-16 Amaxa program). The cells were 
given various treatments with cytokine mTSLP in ng/ml. 
mIL-3 (10 ng/ml) serves as a positive control for the 
reporter gene. SD is derived from duplicate samples and 
shown as error bars. Shown are representative data from 
three independent experiments. 
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4.1.3. Probing the effects of relative rotation of TSLP receptor chain domains on 
induced reporter gene activation 
 
There was further scope of improvising the Ba/F3 luciferase readout system by relative rotation of 
the transmembrane domains (Bell et al., 2000) of the inner hybrid human chains as shown by 
Wohlmann (Wohlmann, 2014) in case of human TSLP chains. To test the possibility that the signal 
intensity of the Ba/F3 system could be further enhanced, the clones were prepared by Wolhlman by 
introducing internal human chains which had 1-4 amino acid extra in the transmembrane domain. 
One amino acid twisted the chain by 110° changing the spatial confirmation in such a way to increase 
the final luciferase activity several folds higher (see Fig. 4.6). The effective rotations, compositions 
and various possible combinations of these chains are listed in the table 4.1.  
        Table 4.1(a). Composition of chains with rotated domains (b) combination of chains 
Domain combination Name  Rotation (in degrees) 
exo-mTSLPR-intra hTSLP + 4AA T5 +440 
exo-mTSLPR-intra hTSLP + 3AA T6 +330 
exo-mTSLPR-intra hTSLP + 2AA T7 +220 
exo-mTSLPR-intra hTSLP + 1AA T8 +110 
Domain combination Name  Rotation 
exo-mIL-7-intra hIL-7+ 4AA 71 +440 
exo-mIL-7-intra hIL-7– native 72 + 0 
exo-mIL-7-intra hIL-7+ 2AA 73 +220 
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For studying the functional properties of these chains, the various combinations of the plasmids 
expressing these chains (5 microgram) were transfected separately into 1 million/ml Ba/F3 cells 
using Amaxa T-16 program. The various combinations are listed in the table 4.1 b above. 
All the combinations of cells were treated with 20ng/ml of mTSLP. After 16 h they were lysed and 
the relative luciferase activity was determined through a luminometric analysis. The results obtained 
are shown in Fig 4.6 b.  









































































Fig.4.6. Effects of relative domain rotations in the transmembrane region. a. Schematic representation of the domain 
rotated hybrid chains. b. Luminometric analysis of relative luciferase activity on Ba/F3 readout (for experimental details 
see text). SD is derived from duplicate samples and shown as error bars. Shown are representative data from three 
independent experiments. 
_______________________________________________________________________________________________ 
The combination T8/73 gave signals 5 fold higher as compared to the native chains without insertion 
of amino acids. The possible combination thus obtained can provide better resolution of signaling 
activity in the luciferase assay and used for further studies. 
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4.2. Cloning, expression, purification and characterization of the exo-domain of 
the TSLPR chain and its use in producing an anti-mouse TSLPR antibody 
4.2.1. The purpose of production and cloning of mTSLPR exo-domain protein 
 
Murine Thymic stromal lymphopoietin (mTSLP) is a cytokine produced by the epithelial cells at 
barrier surfaces. mTSLP acts as a pivotal axis of the inflammatory responses by immune cells in the 
development of chronic inflammatory disorders such as asthma and atopic dermatitis (see section 
1.Introduction). TSLP establishes extensive interfaces with its cognate receptor (TSLPR) and the 
shared interleukin 7 receptor α (IL-7Rα) chain to induce a membrane-proximal receptor complex 
poised for intracellular signaling. TSLP binding to TSLPR is a mechanistic prerequisite for the 
recruitment of the IL-7Rα chain to the high-affinity ternary complex, which is coupled to a structural 
signaling switch in TSLP at the crossroads of the cytokine-receptor interfaces. Further functional 
studies of the TSLP-receptor interfaces can lead to putative interaction hotspots which could be 
exploited for designing antagonists. 
The purpose of cloning exo-mTSLPR domain was to use it as an antigen for immunizing rats for the 
generation of anti murine TSLPR antibodies, as an active inhibitor for blocking mTSLP signaling 
and for testing the bioactivity of mTSLP-MBP wild and mutant I37E mTSLP-MBP fusion proteins.  
Cloning: The cDNA sequence to the exo-mTSLPR-domains was obtained from NCBI Gene 
database. The expression vector pcDNA3.1 exo-mTSLPR was designed using program Ape editor. 
The gene was amplified using Phusion polymerase PCR reaction from the plasmid pcDNA3.1 
mTSLPR (containing code for murine native TSLPR chain), spleen and liver gDNA (see Fig. 
4.7).The primers used were: exo-mTSLPR-His8xTraN For , exo-mTSLPR-His6x For and RP exo 
mTSLPR Rev (see 3.1.11). 
 
 
Fig.4.7. Production of insert exo-mTSLPR by Phusion PCR. An agarose gel showing the products obtained via a 
Phusion polymerase chain reaction (PCR) using primers as described above in a PCR program (see materials and methods 
section 3.2.10. for conditions). The desired product is visible as a band at 642 Bp in length. 
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The exo-domain insert thus obtained was cloned into the pJet plasmid, verified by colony PCR and 
sequencing for the accuracy of the sequence and then cloned into pcDNA 3.1-hTSLPR by excising 
the inserts by Xho1 and Not 1. The constructs thus obtained from this cloning appeared as shown in 
Fig 4.8 a and b. This cloning was performed by Simone. The expression plasmids contain the signal 
sequence and tags as shown in Fig 4.8 a. and b. see appendix for maps. 
 
 
Fig.4.8 a. Schematic linear illustration of exo-mTSLPR His6x plasmid gene sequence including restriction sites. The 
DNA segment was arranged in the order: BamH1 (5Bp), Xho 1(7 Bp), signal peptide (74 Bp), mTSLPR ectodomain 642 
bp. Not1 (8Bp), Serine Glycine Linker SGL, His6x (18 Bp) and Xba SSE enzyme (68Bp). The His6x-tag to could be used 




Fig.4.8 b. Schematic illustration of exo-mTSLPR-8x His TraN sequence including restriction sites. The DNA segment 
was arranged in the order: BamH1 (5 Bp), Xho1(7 Bp) signal peptide74 Bp, mTSLPR ectodomain 642 Bp. Not1 (8 Bp); 
His8x (24 Bp) TraN (48 Bp) Xba SSE enzyme (68 Bp).The TraN and His8x-tag could be used in the detection and 
purification of the ectodomain protein. The sequence is cloned in pcDNA3.1 expression vector. 
 
4.2.2. Expression of mTSLR exo-domain protein 
 
A stable cell line was prepared by transfecting the recombinant plasmid thus obtained into HEK 
293T cells by using a. Amaxa Nucleofactor and b. Turbofect. The program used was A-23. For 
transfection protocols refer to section 3.3.7. The stable cells were selected via resistance against 
antibiotic zeocin in DMEM medium for a week. Cells which were successfully transfected survived 
in zeocin containing medium and these were frozen at -80°C in 10% DMSO, 20% FCS and 70% 
DMEM. A few aliquots were taken and grown (1 million/ml cells) in medium DMEM 10% FCS, 
1% Gentamycin in 75 sq m flasks till confluence. The supernatant was harvested every 4th day 
(yellow in appearance). The cells were split 1:10 and reused. Relative protein production as an 
indicator for the transfection efficiency was checked by SDS PAGE (see Fig 4.9). 





Fig.4.9. Western blot analysis showing comparative expression of mTSLPR in HEK 293T cells transfected with 
pcDNA3.1 exo-mTSLPR-His 8xTraN by Amaxa and Turbofect. The western blot shows the expression of mTSLPR in 
supernatants from stably transfected HEK293T cells with pcDNA3.1-mTSLPR-His8xTraN. The transfection methods used 
were a. Amaxa Nucleofactor and b. Turbofect. Anti-Histidine antibody (Qiagen) was used as primary and goat anti mouse 
Ab (Santa Cruz) was the secondary Ab used for detection of the bands. Positive control: hTSLPR-His Tag Negative control: 
Loading buffer. The cells transfected with Turbofect showed better expression of protein. 
_______________________________________________________________________________________________ 
 
The western blot analysis shows that the cells transfected via amaxa showed lesser expression of 
protein as compared to those transfected by Turbofect transfection medium. This shows that the 
transfection method is critical to the production of the proteins. Therefore, the scaling up of 
production of exo-mTSLPR was done with cells transfected with Turbofect®.  
4.2.3. Production and purification of mTSLPR exo-domain protein  
 
The stable HEK 293-exo-mTSLPR-His8x-TraN cells obtained as above were grown (1 million/ml 
cells) in 175 sq. cm flasks in DMEM medium with 10% FCS and 1% gentamycin till confluence. 
The antibiotic resistance was maintained by adding zeocin in 1 microgram per ml. The supernatant 
was harvested every 4th day (yellow in appearance). The supernatants were spun in centrifuge at 
4500 rpm for 15 min, filtered and stored at minus 20°C in 1 litre bottles till purification via affinity 
chromatography through the His8x tag-nickel fast flow column interactions.  
The supernatant was then dialyzed at 4°C overnight inside the dialysing bags in Na-Phosphate Buffer 
(pH 8.0) and proceed for further purification on ÄKTA explorer purification system via Ni-Affinity 
chromatography and a western blot was run to detect the protein in the eluted fractions. It was 
observed that the protein was eluted in the range from 25% to 70% of the Imidazol gradient elution 
(see Fig. 4.10). The purity of the sample was assessed via a silver gel (see Fig. 4.11). For dialysis 
and silver gel protocols, please refer to sections 3.4.3 and 3.4.5. 
Anti His tag 
antibody 





Fig.4.10. Purification of exo-mTSLPR-His8xTraN protein on ÄKTA explorer purifiction system. 
a. A chromatogram showing the loading and gradient elution of exo-mTSLPR-His8xTraN protein based on the affinity of 
the protein´s His tag towards nickel coated matrix on the fast flow separation column. The various phases of loading and 
elution of the protein are indicated in the diagram. The supernatant obtained from HEK 293-exo-mTSLPR-His8x-TraN 
cells was loaded over a Ni-Fast flow column, washed and then the protein eluted. The elution was made by step gradient 
increase of Imidazol concentration percentage in the Na-Phosphate buffer. (pH 8.0).  
b. A western blot showing the elution performed via a stepwise increasing gradient of Imidazol (expressed in percentage 
where 100% equals to 500mM). The eluted fractions were analysed by staining with anti His tag antibodies. His tagged 
human TSLPR serves as a positive control. 
_____________________________________________________________________________ 
 
The fractions thus obtained were mixed to obtain final 3 fractions. The proteins were further dialysed 
(for protocol see materials and methods section 3.4.4) in PBS by putting them in dialysis bags 
overnight at 4 ºC. The proteins were further concentrated by spinning them on Millipore concentrator 
tubes (cutoff 30000 daltons). The concentrated proteins thus obtained were frozen at  
-20 ºC. 
                                                                                                                                                                                          




Fig.4.11. Analysis of mTSLPR production via western blot and silver gel analysis. a. Western blot (stained with anti-
His tag antibody) showing the purified and concentrated exo-mTSLPR-His8xTraN fractions as obtained via purification 
in 4.10. b. silver gels showing purified murine TSLP receptor protein (indicated by the arrows). Silver gels were run to 
assess purity of the sample. Approximately 1.5 litres of supernatant was used for this purification. 
_________________________________________________________________________________________________ 
4.2.4. Characterization of the ligand binding properties of exo-mTSLPR protein 
 
The exo-mTSLPR protein which is obtained as purified above is characterized for its binding 
properties towards the mTSLP-MBP fusion protein (see production and purification in results section 
4.3) by an ELISA. The scheme for ELISA is illustrated in Fig 4.12. An immunoabsorbent 96 well 
ELISA plate was coated with wild type mTSLP-MBP fusion or commercial TSLP mixed with PBS 
overnight. The plate was then treated with exo-mTSLPR in increasing concentrations (Fig 4.13) and 
the binding quantified by detecting the His tag via anti His and HRP conjugated secondary antibodies 
and substrate (TMB-Citrate buffer) reaction. 
 
Fig.4.12. Schematic representation of ELISA to detect the binding activity of exo-mTSLPR His8xTraN to its ligand 
murine TSLP-MBP/commercial TSLP. The plate was coated with mTSLP (fusion or commercial). The His tag was 
detected via primary anti His tag antibody and secondary anti HRP conjugated antibody. TMB-citrate acid buffer was used 
as a substrate. 




Fig.4.13. ELISA based analysis to detect the binding activity of exo-mTSLPR to its ligand murine mTSLP-MBP 
/commercial TSLP. The plate is coated with mTSLP-MBP (100ng/well) in PBS. The mTSLPR was added in different 
dosages as shown in the graph followed by washings with PBST. The mTSLP which binds to the cells is detected via 
primary anti His tag antibody and secondary anti HRP conjugated antibody. The TMB-citrate acid buffer was used as a 
substrate for HRP and produced a blue color which turned yellow on addition of 2M H2SO4. 50 ng/ml commercial TSLP 
coated well acts as a positive control. 100 μg/ml TSLPR is added to this well. 
_______________________________________________________________________________________________ 
It is observed that mTSLPR-exo shows binding towards mTSLP-MBP and commercial mTSLP in a 
dosage response curve to reach saturation at 100μg/ml.  
4.2.5. Characterization of the biological activity of the exo-mTSLPR in a Ba/F3 cell 
Luciferase assay  
 
The mTSLPRexo-domain protein obtained was checked for biological activity by using it as a 
competitor against mTSLP which binds to the TSLPR receptor present on the Ba/F3 cells.  
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Fig.4.14. A Ba/F3 cell Luciferase assay to prove whether the exo-mTSLPR-His8xTraN is bioactive. The Ba/F3 
reporter gene cells were treated with 50 ng/ml of commercial TSLP and then increasing dosages of exo-mTSLPR. hTSLPR 
(100μg/ml) treatments were given to ensure that mTSLPR-mTSLP interactions are specific. 
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It was observed that the luciferase signal is impeded as we increase the dosages of the mTSLPR. 
hTSLPR (100μg/ml) has no effect on the cells thus proving that the mTSLPR-mTSLP interactions 
are specific. This shows that the exo-mTSLPR domain is active and actively competes with mTSLP 
and prevents it from bindings to the TSLP receptors present on the cell. 
4.2.6. Production and specific binding characterization of rat anti mouse-TSLPR 
antibody 
 
Monoclonal antibodies against target receptors have been used as valuable therapeutics in recent 
times. An antibody that binds to the exo-mTSLPR domain could either be an inhibitory antibody or 
serve the purpose of being used as a detection antibody when coupled to a fluorophore. The exo-
mTSLPR protein as produced above was used also to produce an antibody by outsourcing the entire 
immunization in rats and production strategy to our collaboration partners. The strategy applied for 
antibody generation is shown in Fig. 4.14. 
 
Fig.4.15. A schematic representation of production of rat anti exo-mTSLPR-His8x TraN. The protein after production 
from the stable cell line as described above was used to immunize rats. The resulting hybridomas were screened and 
antibody was produced by conventional methods defined. 
________________________________________________________________________________________________ 
The rat anti mouse mTSLPR antibody was produced and provided to us for testing. The antibody 
was provided in two forms, biotinylated and non biotinylated. The antibody was tested for binding 
by transfecting 1 million cells Ba/F3 cells with only mTSLPR chain expressing plasmid. These cells 
were allowed to grow for 16 h, washed and were treated with 1μg of anti mTSLPR antibody. The 
cells were then washed again and stained with goat anti rat IgG-PE secondary antibody. A control 
experiment was also done to ensure if the TSLPR chain was expressed by detection of the P5D4 tag 
on the surface of the transfected cells (a-c. The signals were detected by flow cytometry and analyzed 
using the Cyflogic software. The results obtained are shown in Fig. 4.16. 




Fig.4.16. Flow cytometric analysis of specific binding characteristic of rat anti mTSLPR. Two sets of 1x106 cells 
Ba/F3 cells were transfected with empty vector pcDNA3.1 and pcDNA3.1-mTSLPR and the cells were grown overnight 
for 16 h. 20000 cells were detected on flow cytometer. a-c. show control experiment for detection of mTSLPR expression. 
The detection was made withanti-P5D4- secondary goat anti mouse IgG-PE antibody. The P5D4 tag is expressed on the 
surface at the N terminal region of the chain and provides readout for detection of chain expression.     d-f. show specific 
binding characterization of the rat anti-mTSLPR. After expression on the surface of Ba/F3 cells of mTSLPR was confirmed 
by checking the cells for P5D4 tag expression, the cells were then stained with rat anti-mTSLPR and then with secondary 
goat anti rat IgG-PE. The figure d- shows dot plot of cells which are transfected with empty vector and which don’t express 
mTSLPR. The figure e represents dot plot from cells transfected with pcDNA 3.1- mTSLPR and which expressed 
mTSLPR. The figure f- shows the ovelay histogram from samples shown in d and e. 
_______________________________________________________________________________________________ 
The dot plots and overly 4.16 a-c show that transfected Ba/F3 cells expressed mTSLPR after 16 h 
while the dot plots and overlay 4.16 d-e shows that the rat anti mouse anti mTSLPR could bind 
successfully to the mTSLPR chain. The overlay 4.16 c shows a strong shift in signal indicating the 
binding of antibody to the receptor chain. Thus, after confirming the binding properties, the antibody 
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was tested in a Ba/F3 Luciferase based mTSLP activity inhibition assay for inhibitory properties. It 
was found that it was non-inhibitory in nature (data not shown).  
4.3. Cloning, expression, production and characterization of mTSLP and I37E 
mTSLP mutant using the pMAL system  
 
mTSLP was needed to be produced so as to ensure an inexpensive and constant supply for in vitro/in 
vivo studies related to mTSLP signaling. It also had to be used during biological testing of binding 
studies related to mTSLPR. Therefore a need arose for this protein to be produced in the lab. The 
initial approaches to produce mTSLP were taken by Andreas Borowski (personal communication) 
were not successful. The bacterial expression of this protein yielded inclusion bodies and after their 
lysis, the protein produced using Sepharose G column was not active. The eukaryotic expression was 
tried in the HEK cells using vectors pcDNA3.1 mTSLP-CD14 signal peptide and pcDNA3.1 
mTSLP, did not show any expression on Western blot (data not shown).  
 
4.3.1. Cloning of pMALp2X/c2X-mTSLP constructs  
 
Guan, C. et al. (1987) for the first time described a method for expression of proteins as fusion 
proteins attached to C terminus of MBP and purification by binding to cross linked amylose. The 
pMAL vector system is a convenient way of expressing proteins as fusion protein with MBP. The 
system has been described in materials and methods section 3.2.  
 
In order to produce the mTSLP-MBP fusion protein in the pMAL-2 vectors, the mTSLP gene was 
inserted into the pMAL-2 vectors in a way that it is in the same translational reading frame as the 
vector’s malE gene. Software Ape was used for the purpose. There were 2 different set of vectors 
which were used:  
 
The pMAL-c2X was obtained from colleagues in from Experimental Animal Center, Institute of 
Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, PR China. The 
construct was ready to be used for production of mTSLP. The plasmid DNA was amplified via 
transformation into E. coli Top 10 (for detailed protocol, see material and methods 3.1) cells and a 
plasmid DNA mini prep was done. The sequence was obtained via sequencing of the plasmid DNA. 
The malE primer which initiates sequence near the 3´ end of malE, 78-81 bases upstream of the 
primary site in the polylinker, was used for sequencing the plasmid DNA. After ascertaining that the 
sequence matches to the sequence from NCBI, the plasmid DNA was then used to transform BL-21 
DE3 strain (Novagen) cells. These transformed bacteria were directly used for the production of 
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mTSLP by IPTG induction as described in the materials and methods 3.4.6. This construct secretes 
the protein in cytoplasm. 
 
The pMAL-p2X vector was obtained as pMAL-p2X-cMPL ectodomain construct from Sebastian 
Krause, Invigate. This construct secretes the protein in the periplasmic space. Since a comparison of 
protein secretion efficiency was desired between the cytoplasmic and periplasmic spaces, this vector 
was modified to insert the mTSLP gene as described below.The software Ape was used for designing 
the construct map for pMAL-p2X-mTSLP and the primers mTSLP-MBP For (p2X) and mTSLP-
MBP-Rev (p2X). These primers were then used to amplify the mTSLP gene from pASKIEP-mTSLP 
construct as a template. These primers were used to initiate a Phusion Polymerase PCR reaction 
using the program as listed in materials and method. This construct pMAL-p2X-cMPL was modified 
by excising the cMPL ectodomain using restriction enzymes Eco RI and Hind III and inserting the 
mTSLP protein expressing gene (see Fig. 4.17). The cloning was performed by Karstern Letsch. The 
ligated plasmid thus obtained was transformed into E. coli Top 10 cells and the cloning effectiveness 
was verified by a colony PCR. The positive clones were selected and then their plasmids isolated by 
mini prep. The plasmid DNA was sent for sequencing to verify the sequence. The malE primer which 
initiates sequence near the 3´ end of malE, 78-81 bases upstream of the primary site in the polylinker, 
was used for sequencing the plasmid DNA. After making sure that the sequencing yielded no error, 
the plasmid DNA was used for protein production by transformation into BL-21 DE3 strain (see 
materials and methods 3.4.6 for details).  
 
 
Fig.4.17. Schematic representation of cloning scheme showing the preparation of the pMALp2X-mTSLP vectors. 
The plasmids pMALp2X-cMPL was restricted with EcoRI and Hind III enzyme treatments. The inserts were generated by 
a PCR. The insert was ligated in the restricted pMALp2X vector. The end results of the cloning were final vectors 
pMALp2X-mTSLP. 
________________________________________________________________________________________________ 
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4.3.2. Expression and purification of mTSLP-MBP fusion protein 
 
The two construct as above: pMALp2X-mTSLP and pMAL-c2X-mTSLP from the Chinese 
colleagues, were transformed into BL-21 DE 3 (Novagen) competent bacterial cells and were plated 
on an Agar plate with Ampicillin resistance (100μg/ml Ampicillin resistance) and incubated at 37°C 
(for protocols see material and method 3.2.1 and 3.2.2).  
The protein production was initiated by induction with IPTG 1M at an O.D. of 0.5, for 1 litre of the 
bacterial culture. 6 h later the cells were harvested by spinning the cells down at 4000 rpm for 20 
min. A coomassie gel (for protocol see material and methods 3.4.2 was run with induced and 
uninduced samples of bacteria to check for the success of induction. The results are shown in 
Fig.4.18 below:  
The weight of the MBP is 42.5 kDa and that of mTSLP is 15 kDa so together, the weight of the 
fusion protein shall be 57.5 kDa and we must expect a band in the coomassie blot at this level for 
the mTSLP-MBP fusion protein. 
                                               
Fig.4.18. Coomassie blot analysis of IPTG induction of BL-21 DE3 cells carrying pMAL-2 series constructs with 
mTSLP insert.1 litre of bacterial culture was inoculated with 50 ml of the respective overnight bacterial culture and 
induced with 1M IPTG at OD 0.5 and shaken for 6 h after induction. a. Comparison of pMAL-p2X-mTSLP-BL21 DE3 
bacteria samples (uninduced and induced) in different lanes b. Comparision of pMAL-c2X-mTSLP-BL21 DE3 bacteria 
samples (uninduced and induced) in different lanes. 20 μl of the bacterial culture was mixed in 50 μl of loading dye and 
out of this mixture 20 μl is loaded on the gel (Fig. from Karstern Letsch, unpublished results). 
pMAL-p2X-mTSLP-BL21 DE3 and pMAL-c2X-mTSLP-BL21 DE3 both show induction as 
evident by the dark band on the Commassie gels at approximately 57.5 kDa. 
Purification by affinity chromatography from the periplasmic/cytoplasmic extracts  
The protein laden cells obtained above were harvested by spinning on the centrifuge them at 4000 
rpm for 20 min and the samples prepared respectively as described in the materials and methods. 
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protein mTSLP-MBP was eluted as fractions of volume of 500 μl each (around 5 ml of elution buffer 
was used so as to produce 10 fractions of eluted solution). The protein samples could be dialysed in 
the dialysis buffer (10 mM Tris-HCl; 50 mM NaCl; pH 8.0) depending upon the usage.  
The proteins samples were run over a 12.5% SDS gel and a Coomassie staining was performed (see 
Fig.3.2.2). The concentration of the protein was determined by measuring the concentration on the 
Nanodrop spectrophotometer or a Bradford assay. Prot Param tool was used to get the actual 
concentration by dividing it with the extinction coefficient. The value of extinction coefficient is 1.4 
for mTSLP-MBP protein. 
For the periplasmic expressed protein samples shown in figure, the concentration of protein was 2.5 
mg/ml. Therefore, the yield from 1 litre of bacterial culture was approximately 2.5x10= 25 mg.  The 
coomassie gel showed additional bands and this perhaps point out that the protein undergoes 
degradation or half trancribed protein fractions are produced.  
For the cytoplasmic expressed protein samples shown in figure, the concentration of protein was 7 
mg/ml. Therefore, the yield from 1 litre of bacterial culture was approximately 7x10= 70 mg. The 
coomassie gel showed a distinct band at 57.5 kDa which is the desired protein size. Therefore the 
cytoplasmic expression of protein yields almost 3 times more protein. 
a.                    b.  
Fig.4.19. Coomassie blot analysis of purified elutes obtained from pMAL-2 series constructs with mTSLP insert. 1 
litre of culture was inoculated with 50 ml of the respective overnight bacterial culture and induced with 1M IPTG at OD 
0.5 and shaken for 6 h after induction. The cells lysates/periplasmic preparations were passed over amylose column and 
washed with lysis buffer. After this the protein mTSLP-MBP was eluted by Elution buffer a. pMAL-p2X-mTSLP-BL21 
DE3 bacteria produced mTSLP-MBP from the periplasmic extract which are eluted in fractions of 500 μl each. b. pMAL-
c2X-mTSLP-BL21 DE3 cell lysate extract also shows protein production in elutes of fractions of 500 μl. 10 μl of each 
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4.3.3. Characterization of binding activity of mTSLP-MBP protein  
 
The fusion protein thus produced above was tested for its binding activity. This was done by an 
ELISA in which the plate was coated with a fixed amount (500ng/well) of mTSLP-MBP. The various 
dosages of mTSLPR were then added in increasing dosages. The mTSLPR which binds to the 
mTSLP-MBP can be detected by antibodies against His tag on mTSLPR and secondary Ab Goat 
Anti mouse IgG-HRP conjugated. The results obtained are shown in Fig. 4.20. 
 
 
Fig.4.20. ELISA based analysis to detect the binding activity of exo-mTSLPR to its ligand mTSLP-MBP. The plate 
is coated with mTSLP-MBP (50ng/well) in PBS. The mTSLPR was added in different dosages as shown in the graph. The 
mTSLP which binds to the cells is detected via primary anti His tag antibody and secondary anti HRP conjugated antibody. 
The MBP amount is 50ng/well. 
________________________________________________________________________________________________ 
 
It was observed that the mTSLP-MBP protein binds to the mTSLPR in a dose dependent manner.  
4.3.4. Activity assay on Ba/F3 cellular test system 
 
After confirming the binding characteristics of the mTSLP-MBP protein with an ELISA, the 
bioactivity was determined by using a Luciferase gene based assay. Approximately 1 million cells 
starved Ba/F3 cells were transfected with plasmids expressing plasmids expressing hybrid chains 
exo-mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-7Rα hybrid and IRF-Luc reporter 
gene. They were treated with mTSLP-MBP in various dosages as a gradient. The cells were grown 
for 12-16 h, lysed and reporter gene activity determined on a luminometer. The results obtained are 
shown in Fig 4.21. 




Fig.4.21. Analysis of Ba/F3 luciferase gene based readout to determine the relative bioactivity of mTSLP-MBP 
fusion protein. The plasmids expressing hybrid chains exo-mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-7Rα 
hybrid and IRF-Luc reporter gene were transfected in the Ba/F3 cells using T-16 Amaxa program. The cells were given 
various treatments with cytokine mTSLP-MBP in ng/ml. The cells were grown for 16 h, lysed and luciferase activity 
determined on Luminometer. mIL-3 (10 ng/ml) serves as a positive control for the reporter gene. SD is derived from 
duplicate samples and shown as error bars. Shown are representative data from three independent experiments. 
_______________________________________________________________________________ 
 
It was observed that mTSLP-MBP is bioactive and it produces a dosage dependent activity in the 
reporter gene system. A bioactive form of murine TSLP is obtained which does not have a high 
specific activity, but it could be used in relative studies aimed at designing antagonistic mutants. 
4.3.5. Cloning of pMALp2X/c2X-I37EmTSLP construct for generation of a potentially 
antagonistic mutant 
 
Fig.4.22. Schematic representation of cloning scheme showing the preparation of the pMAL-mTSLP vectors for 
preparation of mTSLP-MBP fusion protein. The plasmids pMAL-p2X-cMPL and pMAL-c2X-mTSLP were restricted 
with EcoRI and Hind III enzyme treatments. The mutation I37E coding inserts were generated by causing a mutation in 
the sequence using mutation PCR. The end results of the cloning were final vectors pMAL-p2X-I37EmTSLP and pMAL-
c2X-I37EmTSLP. 
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The software Ape was used for designing the construct map for pMAL-c2X-I37EmTSLP and 
pMAL-p2X-I37EmTSLP and the primers I37E mTSLP-MBP For (c2X/p2X), I37E mTSLP-MBP 
Rev (c2X), I37E mTSLP-MBP Rev (p2X). These primers were then used to amplify the I37E 
mTSLP mutant gene from pASKIEP-mTSLP construct as a template. These primers were used to 
initiate a Phusion polymerase medicated mutation PCR reaction using the program as listed in 
materials and method section 3.2.10. The construct pMAL-p2X-cMPL was modified by excising the 
cMPL ectodomain using restriction enzymes (see fig 4.22) Eco RI and Hind III and inserting the 
I37E mTSLP protein expressing gene. The ligated plasmid thus obtained was transformed into E. 
coli Top 10 cells and the cloning effectiveness was verified by a colony PCR. The positive clones 
were selected and then their plasmids isolated by mini prep. The plasmid DNA was sent for 
sequencing to verify the sequence. The malE primer which initiates sequence near the 3´ end of 
malE, 78-81 bases upstream of the primary site in the polylinker, was used for sequencing the 
plasmid DNA. After making sure that the sequencing yielded no error, the plasmid DNA was used 
for protein production by transformation into BL-21 DE3 strain (see materials and methods for 
details).  
 
4.3.6. Expression and purification of I37E mTSLP-MBP fusion protein  
 
The two constructs as above: pMALp2X-I37EmTSLP and pMAL-c2X-I37EmTSLP, were 
transformed into BL-21 DE 3 (Novagen) competent bacterial cells and the protein production was 
carried out in a similar way as described above for mTSLP-MBP fusion protein.The molecular 
weight of the MBP is 42.5 kDa and that of I37E mTSLP is 15 kDa so together, the molecular weight 
of the fusion protein shall be 57.5 kDa and we must expect a band in the Coomassie blot at this level 
for the mTSLP-MBP fusion protein. 
                                                        
Fig.4.23. Coomassie blot analysis of IPTG induction of BL-21 DE3 cells carrying pMAL-2 series constructs with 
I37E mTSLP insert. 1 litre of bacterial culture was inoculated with 50 ml of the respective overnight bacterial culture and 
induced with 1M IPTG at OD 0.5 and shaken for 6 h after induction. a. Comparison of pMAL-p2X-I37EmTSLP-BL21 
DE3 bacteria samples (uninduced and induced) in different lanes b. Comparison of pMAL-c2X-I37EmTSLP-BL21 DE3 
bacteria samples (uninduced and induced) in different lanes. 20 μl of the bacterial culture was mixed in 50 μl of sample 
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pMAL-p2X-I37EmTSLP-BL21 DE3 and pMAL-c2X-I37EmTSLP-BL21 DE3 both show 
induction as evident by the dark band on the Commassie gels at approximately 57.5 kDa. 
Purification by affinity chromatography from the periplasmic/cytoplasmic extracts: 
The protein production was carried out in a similar way as that for the mTSLP production. The 
protein samples could be dialysed in Dialysis buffer (10 mM Tris-HCl; 50 mM NaCl; pH 8.0) 
depending upon the usage. The proteins samples were run over a 12.5% SDS gel and a Commassie 
staining was performed (see Fig. 4.24). The concentration of the protein was determined by 
measuring the concentration on the Nanodrop spectrophotometer or a Bradford assay. Prot Param 
tool was used to get the actual concentration by dividing it with the extinction coefficient. The value 
of extinction coefficient is 1.4 for I37E mTSLP-MBP protein.For the periplasmic expressed protein 
samples shown in figure, the concentration of protein was 3 mg/ml. Therefore, the yield from 1 litre 
of bacterial culture was approximately 3.1 x10= 31 mg. The coomassie gel showed additional bands 
and this perhaps point out that the protein undergoes degradation or half transcribed protein fractions 
are produced. For the cytoplasmic expressed protein samples shown in figure, the concentration of 
protein was 8.1 mg/ml. Therefore, the yield from 1 litre of bacterial culture was approximately 
8.1x10= 81 mg. The coomassie gel showed a distinct band at 57.5 kDa which is the desired protein 
size. Therefore the cytoplasmic expression of protein yields almost 3 times more protein. 
a.             b.  
Fig.4.24. Coomassie blot analysis of purified elutes obtained from pMAL-2 series constructs with I37E mTSLP 
insert. 1 litre of culture was inoculated with 50 ml of the respective overnight bacterial culture and induced with 1M IPTG 
at OD 0.5 and shaken for 6 h after induction. The cells lysates/periplasmic preparations were passed over amylose column 
and washed with lysis buffer. After this the protein I37E mTSLP-MBP was eluted by elution buffer. a. pMAL-p2X-
I37EmTSLP-BL21 DE3 bacteria produced ImTSLP-MBP from the periplasmic extract which was eluted in fractions of 
500 μl each. b. pMAL-c2X-I37EmTSLP-BL21 DE3 cell lysate extract also shows protein production in elutes of fractions 
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4.3.7. Characterization of binding activity of I37E mTSLP protein  
 
The fusion protein thus produced above was tested for its binding activity. This was done by an 
ELISA in which the plate was coated with a fixed amount (500ng/well) of I37E mTSLP-MBP. The 
various dosages of mTSLPR were then added in increasing dosages. The mTSLPR which binds to 
the I37E mTSLP-MBP can be detected by antibodies against His tag on mTSLPR and secondary Ab 
Goat Anti mouse IgG-HRP conjugated. The results obtained are shown in Fig. 4.25. 
 
Fig.4.25. ELISA based analysis to detect the binding activity of exo-mTSLPR to ligand I37E mTSLP-MBP. The 
plate is coated with mTSLP-MBP (50ng/well) in PBS. The mTSLPR was added in different dosages as shown in the graph. 
The mutant I37E mTSLP which binds to the receptor is detected via primary anti His tag antibody and secondary anti HRP 
conjugated antibody. The MBP amount is 50ng/well. 
_______________________________________________________________________________ 
It was observed that I37E mTSLP-MBP protein binds to the mTSLPR in a dose dependent manner.  
4.3.8. Activity assay on Ba/F3 cellular test system  
 
As seen above, it is confirmed that the I37E mTSLP-MBP protein binds to mTSLPR in an ELISA, 
the bioactivity was determined by using a Luciferase gene based assay. Approximately 1 million 
cells starved Ba/F3 cells were transfected with plasmids expressing plasmids expressing hybrid 
chains exo-mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-7Rα hybrid and IRF-Luc 
reporter gene. They were treated with similar dosages of mTSLP and I37E mTSLP-MBP in various 
dosages as a gradient. The cells were grown for 12-16 h, lysed and reporter gene activity determined 
on a luminometer. The results obtained are shown in Fig 4.26 on the next page. 
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Fig.4.26 Analysis of Ba/F3 luciferase gene based readout to determine the relative bioactivity of I37E mTSLP-MBP 
fusion protein. The plasmids expressing hybrid chains exo-mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-7Rα 
hybrid and IRF-Luc reporter gene were transfected in the Ba/F3 cells using T-16 Amaxa program. The cells were given 
various treatments with cytokine mTSLP-MBP and I37E mTSLP-MBP in ng/ml. The cells were grown for 16 h, lysed and 
luciferase activity determined on Luminometer. mIL-3 (20 ng/ml) and mTSLP (various dosages) serves as a positive 
control for the reporter gene. SD is derived from duplicate samples and shown as error bars. Shown are repesentative data 
from three independent experiments. 
____________________________________________________________________________________________ 
It was observed that the mutant shows no activation of the reporter gene in the Ba/F3 cells as 
compared to the wild type. The above results show that the mutant binds to the receptor but does not 
initiates a signal inside the cell. 
4.3.9. Functional characterization of the competitive ability of the mutant on Ba/F3  
cells 
 
The competitive ability of the mutant was confirmed by using a Luciferase gene based assay. 
Approximately 1 million cells starved Ba/F3 cells were transfected with plasmids expressing 
plasmids expressing hybrid chains exo-mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-
7Rα hybrid and IRF-Luc reporter gene. In combination of the activity assay as shown in 4.26 above, 
the transfected cells were treated with two similar dosages of mTSLP (104 and 105) ng/ml and an 
increasing gradient of I37E mTSLP-MBP (102-106) in various dosage combinations. The cells were 
grown for 12-16 h, lysed and reporter gene activity determined on a luminometer. The results 
obtained are shown in Fig 4.27.  




Fig.4.27. Analysis of a Ba/F3 luciferase gene based competition assay between I37E mTSLP-MBP and mTSLP-MBP 
readout for functional characterization of the bioactivity of the mutant I37E mTSLP-MBP. The plasmids expressing 
hybrid chains exo-mTSLPR-intra-hTSLPR hybrid/exo-mIL-7Rα-intra-hIL-7Rα hybrid and IRF-Luc reporter gene were 
transfected in the Ba/F3 cells using T-16 Amaxa program. The cells were given various treatments with cytokine mTSLP-
MBP and I37E mTSLP-MBP in ng/ml. The cells were grown for 16 h, lysed and luciferase activity determined on 
Luminometer.mIL-3 (20 ng/ml) serves as a positive control for the reporter gene. SD is derived from duplicate samples 
and shown as error bars. Shown is a representative data from three independent experiments. 
_________________________________________________________________________________________________ 
 
It was observed that the mutant shows no activation of the reporter gene in the Ba/F3 cells as 
compared to the wild type. The above results show that the mutant binds to the receptor but does not 
initiates a signal inside the cell. The mutant I37E mTSLP-MBP actively competes with the mTSLP-
MBP thereby decreasing the luciferase signal activity of Ba/F3 cells and thus showing that the mutant 
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4.4. Studying and characterizing the biological effect of TSLP/I37E antagonist on 
TSLP responsive dendritic cells.  
The Ba/F3 cellular readout system as discussed in section 4.1 was designed to obtain the relative 
quantification of mTSLP signaling. It does not give a hint about the biological changes it may bring 
about in the morphology and physiological activity of the target cells. Therefore a need for such a 
cellular system existed, which could allow us to treat it with mTSLP and then quickly study the 
changes in the cell via some readout in the form of a dynamic activity of the surface markers. A 
sensitive system shall be one which could have allowed detection of these changes upon treatment 
with a sensitive readout such as by flow cytometry. 
 
Dendritic cells obtained from the BMDCs (bone marrow derived cells) of mouse femur bone provide 
a model for studying the effect of mTSLP. These cells have been observed to exhibit dynamic 
changes in the expression of surface markers such as OX40L, CD80 and CD86, (Segawa et al., 
2014). It has also been observed that TSLP influences the migration (Soumelis et al., 2011) of these 
cells by influencing the production of some chemokines. Therefore, these cells were chosen for 
studying migration effects by mTSLP as well as the biological changes on the cell surface markers 
which occur upon treating them with the antagonistic mutant. 
 
4.4.1. Preparation of the dendritic cells   
 
Dendritic cells were obtained by allowing the BMDCs from the femur of the C57BL/6 black mice 
under aseptic conditions (Madaan et al., 2014) These cells (1 × 106 cell/ml) were allowed to stick to 
plastic surface of the petri dishes and mature under the influence of 20 ng/ml of GMCSF (Granular 
macrophage colony stimulating factor) in RPMI-1640 medium containing 10% heat-inactivated fetal 
bovine serum, penicillin G/streptomycin (50 μg/ml) in a humidified atmosphere of 5% CO2/95% air 
at 37°C for 6 days. The cells were ready on day 7 and this is confirmed by the increase in signals of 
surface marker CD11c+ which was detected on the flow cytometer. The yield of BMDCs on day 0 
was 10x106 cells per femur. The yield of dendritic cells obtained on 6th day was 2x106 cells/per petri 
dish i.e. 6 million cells in total (see section 3.3.1 of material and methods for the entire procedure of 
isolation, maturation and purification of dendritic cells).  
 
4.4.2. Characterization of the murine dendritic cells 
 
The dendritic cells are formed by maturation of the cells over a period of 7 days. During this period 
the cell undergo several morphological and physiological changes under the influence of the cytokine 
20 ng/ml GM-CSF in RPMI-1640 media. The cells which mature into the dendritic cell shall start to 
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float in the medium, where as cells which form the macrophages, usually stick to the base of the petri 
dish. This unique characteristic can be used to concentrate the dendritic cells and eliminate other 
cells. A richer concentration could be achieved by magnetic beads but here they were not used. 
 
In order to characterize the cells as obtained from the method as described above, the cells were 
regularly observed under a microscope and pictures were obtained on various days (day0 - day7) as 
seen in pictures in Figure. 4.28. The pictures show a visible change in the morphology of the cells. 
The cells change their shape from round to irregular shaped cells with dendritic processes. The cells 
appear rolling over the plate. 
 
 
Fig.4.28. Visual characterization of the dendritic cells on a microscope. A snapshot of the microscope (1000x) showing 
the change in the morphology of the BMDCs to dendritic cells on day 0 (inset image top left corner) and day 7. The red 
circle highlights the dendritic cells with visible dendrite processes. 
 
The cells were then further analysed using flow cytometry. The cells were stained as per the protocols 
(see materials and methods section 3.3.10). Three cell samples from day 0 and day 7 were then 
compared for expression of CD11c+ marker which is a characteristic of the dendritic cells (see Fig. 
4.29). Anti mouse CD11c+ marker coupled to PE flurophore was used for this purpose (see materials 
section 3.3.10). 
 
The gating strategy involved a comparison of the histograms of non stained samples with that of the 
stained samples. A range gate PE-A+ was applied on the histograms to demarcate the cells producing 
the signals. These cells which gave signals were traced back on the dot plot and allowed us to know 
where our population of interest laid. The cells that produced positive stained signals were then gated 
and this is the gate that has been used for the samples represented below in a square dot plot with 
FITC and PE filters on X and Y axis. A quadrant Q4 was then defined to enclose the untreated cells 
inside the quadrant. These are the negatively stained cells. A stained cell shall create a signal which 
can be detected by a migrated shift into quadrants Q3 and Q2. The comparative shift along with the 
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statistical count was then observed as a measure of the staining of the 11c+-PE-A+ stained positive 
cells. Similar gating strategy was applied in all the experiments described ahead. 
a.  
b.   
 c.                    
Fig.4.29. Flow cytometry based analysis based characterization of enriched murine dendritic cells. 0.1 million cells/ 
sample were treated with 1μg of rat anti mouse CD11c+ antibody and were measured on flow cytometer as compared to 
the unstained sample.  
a. Gating strategy: The range gates PE-A- and PE-A+ were applied to the histograms of the unstained and stained cells 
(10000 count each sample) to locate the positive stained population on the dot plot. The PE-A+ population gate represents 
the positively stained cells. b. Dots plot analysis: Dots plots showing the BMDCs transforming into dendritic cells as 
compared between unstained and stained samples on day 0 and day 7. The X and the Y axis have filters for PE and FITC 
signals respectively.c. Overlay histogram: An overlay histogram of the PE-A+ signal from dendritic cells obtained on 
day 0 and day 7 in FL-2 PE channel. The blue curve represents the unstained cells and the red represents the 11c+ positive 
cells on day 0 while the orange curve represents the 11c+ positive cells on day 7. 
_______________________________________________________________________________ 
It was observed that the positive stained cells are located in quadrant Q3 and in time span of 7 days 
all of them shift towards quadrant Q3 and Q2. An increase in the number of CD11c+ cells shows that 
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the BMDCs have matured into dendritic cells as already visible in the microscopic observations 
above and the FACS results support the observation made in Fig 4.28. The A shift towards the right 
was observed on day 7 (shown in orange) as compared to day 0 (shown in red) (see Fig. 4.29 c). The 
orange curve has 2 peaks, one that of 11c+cells and other that of 11c+ negative cells The cells thus 
obtained and characterized were then ready for further use as a testing system for biological activity 
of mTSLP. 
4.4.3. Evaluation of the biological activity of mTSLP in the supernatant of the 
keratinocyte derived squamous cell carcinoma cell (KCMH-1)  
 
KCMH-1 is skin keratinocyte derived squamous cell carcinoma cell line obtained from CBA/j mouse 
(Nakamura et al., 1994), (see materials and methods). This cell line was obtained from our colleague 
Dr. Hirasawa from Tohoku University, Sendai, Miyagi, Japan. This cell line is known to produce 3 
ng/ml of natural murine TSLP on stimulation with 30nM of TPA as established by an ELISA 
(Segawa et al.2014). 
  
KCMH-1 cells (1 × 105 cell/ml) were grown in α-MEM medium containing 10% heat-inactivated 
fetal bovine serum, penicillin G/streptomycin (50 μg/ml)  in a humidified atmosphere of 5% 
CO2/95% air at 37°C for 4 days till they attained confluence. The cells were then stimulated with 
30nM of TPA added along with fresh media. The supernatant was collected in 24 h. 
 
A Ba/F3 cell assay was performed to check if the supernatant thus obtained can cause stimulation of 
the luciferase based STAT-1 reporter gene in the cells. Since the supernatant was in volumes greater 
than that which can be held in 6 well plate, 25 sq. m flask for suspension cells were used. The 
plasmids for expressing the hybrid chains and IRF-luc reporter gene were transfected in 1x106 cells 
Ba/F3 cells (T-16 Amaxa program). The transfected cells were resuspended in residual volume of 2 
ml of RPMI-1640 and then were given treatments with various volumes (2, 5, 7 ml) of the mTSLP 
containing supernatant from KCMH-1 cells. The cells were lysed after 16 h and luciferase gene 
activity evaluated on a luminometer. 
 




Fig.4.30. Luminometric analysis of the KCMH-1 supernatant response exhibited by the mTSLPR expressing Ba/F3 
based IRF-luciferase gene readout system. The plasmids for expressing the hybrid mTSLPR/IL-7 α chains and IRF-luc 
reporter gene were transfected in the Ba/F3 cells (T-16 Amaxa program). 1x106 cells were given treatments with various 
volumes of supernatant from KCMH-1 cell (1 ml has approx. 3 ng of mTSLP) as shown in 25 sq. m flasks with residual 2 
ml of RPMI-1640 medium. The cells were lysed after 16 h and the relative luciferase gene activity was evaluated on a 
luminometer.mIL-3 (20 ng/ml) serves as a positive control for the reporter gene (data not shown). SD is derived from 
duplicate samples and shown as error bars. Shown are representative data from three independent experiments. 
_________________________________________________________________________________________________ 
 
The luciferase assay shows an increase in the relative luciferase activity as compared to the untreated 
cells with increasing volumes of the supernatant from TPA activated KCMH-1 cells. The assay 
shows that the biological mTSLP present in the KCMH-1 cell supernatant can activate the Ba/F3 
Luciferase activity thus proving that the KCMH-1 cells could be stimulated to produce active 
biological mTSLP containing supernatant. 
 
4.4.4. Studying the effects of mTSLP-MBP and antagonistic I37E mTSLP-MBP mutant 
on dendritic cell migration  
 
Maria-Isabel Fernanadez (Fernandez et al., 2011) reported that the dendritic cells show migratory 
behavior across the Boyden chamber when treated with mTSLP. In this experiment (see Fig 4.31 a.) 
the mature dendritic cells (1x106) treated with GM-CSF were grown in Boyden migration chamber 
in the upper well in 500 μl volume and in the lower well various treatments (see Fig, 4.31 b.) of 
mTSLP-MBP, I37E mTSLP-MBP, their combinations and MBP as control were given in different 
wells each containing a volume of 1 ml of the RPMI-1640. Cells were grown in RPMI-1640 medium 
containing 10% heat-inactivated fetal bovine serum, penicillin G/streptomycin (50 μg/ml) in a 
humidified atmosphere of 5% CO2/95% air at 37°C for 12 h after treatment. The cells were then 
fixed, mounted on a slide and seen under a microscope (see materials and methods 3.3.11). The 
pictures were taken and can be seen in Fig. 4.31 b. The cells were counted by dividing the observed 
slide area into 3 different parts (see Fig. 4.31 a). The overview of the slide has been shown in Fig. 
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4.31 b.  After counting the cells an approximate quantification analysis was made by plotting the 
values in Excel (Graph Pad Prism software) and obtaining a X-Y bar diagram (see Fig 4.31. c). 
a. 
. 
b .  
 
 





Fig.4.31. a. Schematic representation of an experiment to study the relative dendritic cell migration across a 
membrane in a Boyden chamber under the influence of mTSLP-MBP and I37E mTSLP-MBP. 1x106 GM-CSF 
treated matured dendritic cells are grown in Boyden migration chamber in the upper well and in the lower well various 
treatments of mTSLP-MBP, I37E mTSLP-MBP, their combinations and MBP control are given. The cells were grown for 
12 h after treatment. The cells are then fixed and seen under a microscope.  
b. Analysis of pictures of slides. 1x106 GM-CSF treated matured dendritic cells were grown in Boyden migration chamber 
as shown in 4.27.a and various treatments of mTSLP-MBP, I37E mTSLP-MBP, their combinations and MBP control are 
given as shown in the table in this figure. The cells were then fixed and seen under a microscope. The number of cells was 
counted from three snapshots taken at 1000x magnification (picture data not shown). The counted cells are listed in the 
table.  
c. Statistical analysis of relative dendritic cell migration. 1x106 cells were allowed to migrate under the influence of 
mTSLP- MBP/I37E mTSLP- MBP treatments made. The mean value of three counts from the fixed cells on the slides 
obtained above in 4.27 b. were statistically analysed to obtain a bar diagram. The Y axis represents the relative migration 
(in folds) obtained by mean value analysis as compared to the untreated control. The X axis represents the treatments in 
ng/ml. The error bars represent the difference in counting cells in the three different regions of the slide area. This is a 
representative data from 2 sets of independent experiments.  
_________________________________________________________________________________________________ 
 
It was observed that the dendritic cells migrated under the influence of mTSLP-MBP and this is 
reduced when an increased dosage of mutant I37E mTSLP-MBP is added. This shows that the mutant 
has an inhibitory activity on the migration of the dendritic cells.  
4.4.5. Studying the effects of mTSLP containing supernatants obtained from activated 
KCMH-1 cells on dendritic cells  
 
The initial approach to produce such a system which mimics epithelial secretion of mTSLP in 
asthmatic condition was taken by Segawa et al., 2014 They used a murine epidermal keratinocyte 
cell line (KCMH-1) for the production of natural TSLP upon stimulation with different stimulants 
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 and then read the effect of the supernatant as obtained on the OX40L, CD80 and CD86 ligand 
expression on the surface of the dendritic cells. This system was adopted and applied to study the 
effects on OX40L expression (see Fig. 4.32) and inhibitory effect of the antagonistic mutant I37E 
on expressions of OX40L (see Fig. 4.32) and CD80 and CD86 (see Fig. 4.33, 4.34). 
 
KCMH-1 cells (1 × 105 cell/ml) were grown in α-MEM medium containing 10% heat-inactivated 
fetal bovine serum, penicillin G/streptomycin (50 μg/ml) in a humidified atmosphere of 5% 
CO2/95% air at 37°C for 4 days till they attained confluence. The cells were then stimulated with 
30nM of TPA added along with fresh media. The supernatant was collected in 24 h. 
 
The dendritic cells (1 × 105 cell/ml) were grown in RPMI-1640 containing 10% heat-inactivated fetal 
bovine serum, penicillin G/streptomycin (50 μg/ml) in a humidified atmosphere of 5% CO2/95% air 
at 37°C. The conditioned media produced by the KCMH-1 cells as described above, in a 1:1 ratio 
was used to stimulate the dendritic cells (see Fig 4.32 for the experimental scheme). The cells were 
stained as per the protocol (see materials and methods 3.3.10) and analysed by flow cytometry after 




Fig. 4.32. a. The KCMH- Dendritic cell based model: Schematic representation of the production and stimulation 
of cells. The diagram shows the stimulation of the KCMH-1 (1 × 105 cell/ml) cells by TPA (30nM) and then later 
stimulation of the 1 × 105 dendritic cells by the KCMH-1 supernatant to produce OX-40 L on its surface. 




Fig.4.32 b. Flow cytometric analysis of dendritic cells stimulated by KCMH-1 cell supernatant. The 1x105 dendritic 
cells were stimulated by KCMH-1 cells supernatant for 24 h and were stained by anti mouse 1 μg of anti-OX-40-PE ligand 
antibody. The signal was analysed using flow cytometry.  
 
It was observed that OX-40 ligand expression on the surface of the dendritic cells in KCMH 
supernatant treated cells is upregulated on addition of KCMH-1 cell supernatant as indicated by a 
positive shift in signal towards the right (as indicated by the light blue curve) as compared to the 
basal expression of OX40 ligands on the dendritic cell surface (violet curve). The isotype control 
and the use of the Fc blockers ensure that there is no unspecific binding with the Fc receptors. The 
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4.4.6. Studying the antagonistic effects of I37E mTSLP-MBP mutant on KCMH 
supernatant induced relative OX-40 ligand expression on the dendritic cellular surface  
 
The supernatant of KCMH cells (1:1 ratio) was used to stimulate the dendritic cells as already 
described above in 4.4.5. The relative expression of OX40L was studied after adding I37E m-TSLP-
MBP in 104 and 106 ng/ml dosages. The results are shown in Fig. 4.33 b. 
a.                     
b.                
Fig.4.33. KCMH- Dendritic cell based model used for the analysis of inhibitory activity of mutant I37E mTSLP-
MBP. a. Schematic representation of the competition assay with dendritic cells. A schematic representation showing 
the stimulation of the the 1x105 dendritic cells by the mTSLP containing KCMH-1 supernatant (obtained by treating 1x105 
KCMH-1 cells by 30nM TPA) to produce OX-40 L on its surface and addition of various dosage of mutant I37E mTSLP-
MBP to reduce it. b. Flow-cytometric analysis of the relative OX40L expression on addition of the mutant dosages. 
This relative expression of OX40L was studied after adding I37E mTSLP-MBP in 104 (shown by light green curve) and 
106 (shown by dark green curve) ng/ml dosages. An isotype control (red curve) by IgG1–PE antibody was also performed. 
Cells without antibody treatment are represented by the orange curve. The cells with only medium (RPMI-1640 + α-MEM) 
is represented by a violet curve and cells with only mutant is represented as a pink curve.  
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It was observed that there is a gradual reduction in the relative OX40 L expression with increasing 
dosage concentrations of the mutant. This indicates that the I37E mTSLP-MBP mutant competes 
with the wild type TSLP. An isotype control ensures that there is no unspecific binding with the Fc 
receptors. 
 
4.4.7. Studying the antagonistic effects of I37E mTSLP-MBP mutant on KCMH 
supernatant induced relative expression of allergic surface markers (CD80 and CD86)  
 
The supernatant of KCMH cells (1:1 ratio) was used to stimulate the dendritic cells as already 
described above in 4.4.5. I37E mTSLP-MBP treatments were given in 104 and 106 ng/ml dosages to 
two different samples. A control with only maximum quantity of mutant was also treated. The treated 
dendritic cells were (1 × 105 cell/sample) were grown in an incubator with 5% CO2/95% air at 37°C 
for 24 h. The relative expression of CD80 and 86 were studied after staining the cells with relevant 
protocol (see materials and methods). The results are shown in Fig. 4.34 and 4.35. 
 
 
Fig.4.34. Flow-cytometric analysis of the relative change in the CD80 expression on the surface of dendritic cells 
stimulated by KCMH-1 cell supernatant, on addition of various mutant dosages. 1 × 105 cell dendritic cells were 
stimulated by KCMH-1 cells supernatant for 24 h and were stained by anti mouse CD80 FITC ligand antibody. The signals 
were analysed using flow cytometry. The basal CD80 expression is indicated by green curve. The maximum CD 80 
expression is indicated by the orange curve. The violet and the blue curve represent the CD80 expression on treatment with 
two different dosage of the mutant I37E mTSLP-MBP (104 and 106 ng/ml respectively).The pink curve is the control with 
only maximum dosage of mutant (106 ng/ml). An isotype control (red curve) by IgG1–FITC antibody was also performed 
(red curve) to show specificity of the antibody. The sky blue curve represents the unstained cells. 
 
It was observed that the KCMH-1 supernatant increased the expression of CD80 ligand on the 
surface of the mouse dendritic cells (as indicated by the shift between green and orange curves).  
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The CD80 expression can be brought down significantly brought down by using 106 ng/ml of I37E 
mTSLP-MBP (blue curve).104ng/ml I37E mTSLP-MBP also decreases the CD80 expression and 
thus a dosage dependent decrease of CD80 relative to the increasing concentrations of I37E mTSLP-
MBP is seen. The isotype IgG1–FITC controls assure that blocking of Fc recpetors by the blockers 
is fine and no unspecific bindings take place. 
 
Fig.4.35.Flow-cytometric analysis of the relative change in the CD86 expression on the surface of dendritic cells 
stimulated by KCMH-1 cell supernatant, on addition of various mutant dosages. 1 × 105 cell dendritic cells were 
stimulated by KCMH-1 cells supernatant for 24 h and were stained by anti mouse CD86 FITC ligand antibody. The signals 
were analysed using flow cytometry. The basal CD80 expression is indicated by violet curve. The maximum CD86 
expression is indicated by the orange curve. The sky blue and light green curves represent the CD86 expression on treatment 
with two different dosage of the mutant I37E mTSLP-MBP (104 and 106 ng/ml respectively).The green curve is the control 
with only maximum dosage of mutant (106 ng/ml). An isotype control (light brown) by IgG1–FITC antibody was also 
performed to show specificity of the antibody. The red curve represents the unstained cells. 
 
In case of CD86 also it was observed that the KCMH-1 supernatant increased the expression of 
CD86 on the surface of the mouse dendritic cells (as indicated by the shift between orange and violet 
curves). The CD86 expression could be brought down significantly brought down by using 106 ng/ml 
of I37E mTSLP-MBP mutant (light green curve). The isotype IgG1–FITC controls assure that 
blocking of the Fc recpetors by the blockers is fine and no unspecific bindings take place.These 











5. Discussion  
 
To understand the interaction of a cytokine with its receptor in physiological context, it is necessary 
to have a cellular readout model. Factor-dependent cell lines have been successfully used in the past 
as models to study and characterize the functional expression of various growth factor receptors. 
They have been instrumental in developing bioassays for several cytokines. The reliability of a cell 
line is vital to the development of successful bioassays. The sensitivity of cell lines during an assay 
may vary when maintained in continuous cell culture. The process of transfecting a cell line leading 
to the expression of a cytokine receptor on the surface can be used effectively to create new factor-
dependent cell lines. The Ba/F3 cell system provided a quick responding and convenient model to 
probe the mTSLP signaling pathway and allowed studies related to the effects of the cytokine 
inhibitors on STAT based reporter gene signaling which served as readout. Ba/F3 is an immortalized 
murine bone marrow-derived pro-B-cell line which depends on murine IL-3 as a growth and 
proliferation factor. In the presence of IL-3, Ba/F3 cells show a great resistance towards X-irradiation 
and the cytotoxic drugs etoposide and cisplatin (Collins, 1992). Ba/F3 cells go through apoptotic cell 
death through the caspase independent pathway on withdrawing the growth factor (Wirawan et al., 
2010). The factor dependence can be switched from mIL-3 to another factor by removal of mIL-3 
and transfection of the cells with chains that express relevant cytokine receptors which would be the 
new dependence factor (Daley et al., 1988). This has been observed in various models for studying 
the functional reconstitution of growth factor receptors e.g.: IL-3, IL-5 (Bosward et al., 1999) , GM-
CSF, Macrophage colony stimulating factor (M-CSF) (Metcalf, et al.,1994, Kitamura et al., 1991, 
Lutz et al., 2000) and the Ba/F3 cell line dependent on Epo as a growth factor (Sakamaki et al., 
1992).  
Following the above discussed strategies, initially the cDNA sequences encoding native TSLP 
receptor chains were cloned into pcDNA3.1 and transfected into the Ba/F3 cells. The reporter gene 
expression signals were not optimal for the studies. This technical defect was removed by the 
transfection of the Ba/F3 cells with exo-mTSLPR-intra-hTSLPR/exo-mIL-7Rα-intra-hIL-Rα hybrid 
receptors along with a STAT1 responsive-IRF reporter gene. This yielded stronger signals when 
treated with mTSLP. The maximum signal is approximately 6 folds at saturating concentration of 
mTSLP. Since the internal part of the chains is human, it could associate well with the reporter gene 
used in the cell. This is the closest artificial model which could be produced in the mouse cells 
expressing mTSLPR. Further optimization is possible by the rotation of the intercellular domains by 
introduction of additional amino acids (see results chapter 4.1) based on data from Andreas 
Wohlmann (Wohlmann, 2014).  
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This leads to combinations producing better signals than the original, though the structure and 
orientation of the chains is compromised as compared to the native state. So this may be a 
shortcoming to not be able to show real state receptor orientation but on the other hands this produces 
signal approximately 5 fold stronger. The problem still existing is that the cell line is transiently 
viable for the assays and it is cumbersome to perform assays like proliferation assays as done by 
Borowski with IL-4 receptor expressing Ba/F3 cells. Such assays when tried with a transient cell line 
do not work. It must be also noted that the reporter gene assay works only on using the precise 
amount of DNA for fixed amount of cells for transfections. Therefore, the plan to make mTSLP 
dependent stable cell line would be instrumental in performing assays like proliferation assays and 
reporter gene assay with convenience. The possible introduction of expression vectors that could 
lead to the cytokine production on which the mTSLP-dependent cell line thrives can create an 
autocrine loop and lead to factor independence. This variant can be used to screen hybridomas for 
the production of monoclonal antibodies that inhibit mTSLP-dependent proliferation as one possible 
application. Efforts to make a stable cell line have been tried in past by removing mIL-3 and applying 
mTSLP selection pressure but have failed. The cells showed growth initially but then died. The 
limitations could be overcome by a 2 step selection procedure. The first selection could be based on 
the application of a zeocin antibiotic to obtain cells with domain rotated receptor. Initially the cells 
shall be given mIL-3. After confirming the presence of domain rotated receptors on the cellular 
surface by flow cytometry, the cells shall be put to mTSLP selection to remove the dependence on 
mTSLP. This process is expected to produce a stable cell line which stably expresses domain rotated 
mTSLPR and is mTSLP dependent.  
Soluble receptors can be used as inhibitory tools to disrupt cytokine signaling by competing with the 
cytokine for binding on to cellular receptors e.g. TNF-α (Seckinger et al., 1990). The mTSLPR 
soluble exodomain effectively competed with mTSLP for the binding on the receptors expressed on 
the cells. Therefore it served as a competitive antagonist to interfere with intracellular STAT based 
luciferase reporter gene activation signals. This is evident by the decreasing signals with the increase 
of the receptor exo-domain concentrations. 
mTSLPR production was optimal for use as a competitor but needs to be further purified by gel 
filtration to ensure a better starting material for the production of antibody. As the structure of the 
mTSLPR is known now, the use of critical antigenic epitopes for targeted antibody production is 
also a possible approach.The mTSLPR antibody produced was non inhibitory (data not shown) 
though it showed that it could bind to TSLPR expressed on Ba/F3 cells. In a similar approach, 
Borowski et al. could yield inhibitory antibody producing clones against human TSLPR. The 
probability to find an antibody using such an approach in single attempt is low. Other hosts 
(hamster/mouse) for producing such an antibody could be tried. Another approach to produce 
antibody using autoimmunity against OVA-amine complexes was tried but could yield fewer clones 
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that survived for some days before dying (data not shown). Such approach could also be re-tried with 
modifications. The technique of anti-cytokine auto-vaccination is a powerful tool but has remained 
rather obscure due to various technical problems. A two-step procedure could be used as described 
by Uyttenhove et al., 2011, which is based on use of purified OVA multimers by size exclusion 
chromatography after incubation with glutaraldehyde at pH 6. This is followed by incubation of these 
polymers with the target protein at pH 8.5, this leads to the de-protonation of the reactive amines, 
resulting in complexes that confer immunogenicity to self-antigens. Uyttenhove et al., 2011 
discussed the chemokine granulocyte chemotactic protein-2 (GCP-2)/CXCL6, cytokines GM-CSF, 
IL-17F, IL-17E/IL-25, IL-27, and TGF-β1, and the MMP-9/gelatinase B as examples. Pre-activated 
OVA multimers reactive with amine residues can thus provide an efficient carrier for auto-
vaccination against 9–90 kDa autologous proteins. This can improve the possible yield of antibody 
producing hybridoma clones. In addition to the production of mouse mAb against mouse factors, in 
vivo, auto-vaccination offers an alternative to gene inactivation in studies of in vivo cytokine function 
(Zagury et al., 2003). This approach in principle could allow for concomitant inhibition of several 
cytokines in the same animal, a need for treating the elevated cytokine milieu in Asthma. Another 
approach as described by Kinoshita (Kinoshita et al., 2005) to prepare 4 monoclonal antibodies 
against an antigen, prostate-specific membrane antigen (PSMA), for immunotherapy to prevent the 
in vivo growth of lymph node carcinoma of the prostate (LNCaP) tumor could also yield a method. 
Using computer-aided analysis, they selected the B cell epitopes of PSMA by using various 
correlates of protein antigenicity and secondary structural predictions according to the algorithm 
procedure described by Kaumaya et al., 1994. Those peptides which had the transferrin receptor-like 
domain of PSMA were subjected to analyses. This yielded 4 oligopeptides corresponding to the 
amino-acid residues of PSMA were selected and listed. A BLAST search at NBCI website 
(http://ncbi.nlm.nih.gov/BLAST/Blast.cgi) found 3 out of these peptides unique for human PSMA. 
These peptides were linked to the C-terminal end of the ‘promiscuous’ measles virus fusion protein 
(MVF) by a LSPG linker to obtain a T-cell epitope and B-cell epitope chimera. Solid phase synthesis 
was used to synthesize these oligopeptides followed by purification by HPLC. The molecular weight 
was checked using Mass spectroscopic analysis. These oligopeptides were used to immunize the 
mice and develop hybridomas yielding mAbs against the oligonuleotides. These mAbs were 
specifically targeted to act against the PSMA epitopes. A similar approach could yield oligopeptides 
which could yield antibodies that bind to the mTSLPR or mTSLP at specific hot spots to impede its 
activity. Another approach that can be undertaken is single domain antibody generation (van der 
Linden et al., 1999, Dumoulin et al., 2002). A single-domain antibody comprises of a peptide chain 
approximately 110 amino acids long with one variable domain (VH) of a heavy-chain antibody, or 
of a common IgG. These peptides are heat resistant and have binding affinity towards antigens 
similar to the whole antibodies. They can be derived from camel and sharks. The complementarity 
determining region 3 (CDR3), makes then more soluble in water and provides them an ability to bind 
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epitopes which a normal antibody cannot bind, however a lack of Fc region leads to complement 
system related cytotoxicity (Dolk et al., 2005, Stanfield et al., 2004). A gene library with several 
million clones can be produced by reverse transcription and polymerase chain reaction. A single-
domain gene library from shark could be screened for antibodies which can bind to the mTSLPR 
(Gibbs, 2005). Panning and screening techniques like yeast display, phage display or ribosome 
display could be used to identify the antigen binding clones. 
The mTSLP production as a fusion protein was done as there was problem while producing it in 
bacteria. Similar approaches have been successful for human TSLP but have failed in production of 
murine TSLP, perhaps due to low homology of mTSLP. Using bacterial production in past, the 
protein could be secreted into inclusion bodies in bacteria but it showed no activity when purified on 
a Ni-sepharose column. Similar problems were experienced with IL-4 and refolding buffers and 
altered conditions had to be used (Andreas Borowski, personal communication). The mTSLP 
production as a MBP fusion protein yielded considerable amounts of protein in a small amount of 
time. mTSLP-MBP was bioactive and showed binding to the mTSLPR. The activity of the MBP-
fusion proteins is quite low when compared to the commercial mTSLP (see secteeion 4.3). This 
could be due to the reason that not hundred percent of the total quantity of protein is folded properly. 
This was not a drawback while studying relative effects in luciferase gene assays but may lead to 
issues during the animal studies. Too much volume of proteins cannot be administered to the animal. 
The protein may also be pyrogenic in mice as it may have contamination with bacterial 
polysaccharides. The cleavage of the protein leads to contamination with factor X and needs another 
tedious step for purification. These reasons should serve as a motivation to produce proteins in 
another possible ways like cloning mTSLP in pHL-expression vector and producing it  in eukaryotic 
cell lines like HEK293S MGAT1−/− in (Verstraete et al., 2014) or NS0 cell line from murine myeloma 
(R&D mTSLP product data sheet). Other plasmids which have been used to produce IL-2 family 
cytokines could also be tried.  
To further elucidate the role of TSLP signaling in diseased condition, the effects of TSLPR blocking 
via mutant I37E was evaluated. It was observed that I37E binds to the receptors without activity but 
shows partial competitive effect (see section 4.3). Thus, it is a partial antagonist that competes with 
the wild type mTSLP in cells activated within a certain concentration range. Efforts need to be made 
to characterize some effective mutants that are better than this mutant. The initially used bacterial 
display strategy can be used to characterize some more mutants by random mutations on the hotspot 
sites where the receptor is binding to the cytokine. This could yield double mutants which may bind 
or not bind to the TSLPR chain and need Ba/F3 based screening to identify the perfect candidates. 
In silico approaches could be adopted and use of software (Scrödinger) based characterization of 
mutants based on stimulated molecular docking. One can also think of altering the interface of IL-7 
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and stabilizing ion pair and counter charges. This approach could lead to the production of 
superantagonists which may show better affinity to TSLP receptor and thus act as competitors.  
No natural human cellular model is available for testing TSLP based inhibitory molecules as there 
are no TSLPR present on peripheral dendritic cells generated by monocytes (Würtzen et al., 2011, 
Andreas Wohlmann, personal communication). KCMH-1-Dendritic cell based cellular model was 
generated to serves as a model for screening of potential allergenicity caused by various 
allergens/chemicals. This could also serve as model to test inhibitory tools against mTSLP as shown 
in results section 4.4. This model addresses mTSLP cellular communication network and offers a 
simple approach and mimics the conditions as present in the allergic animal. Further improvement 
in this model could be made by using it in an airway liquid based interface. This shall allow it to 
mimic the cells of the lung. A co-culture with cells is also possible with other population of the blood 
peripheral blood mononuclear cells (PBMCs) and can yield studies based on CD surface marker 
dynamics on these cells under inflammatory condition. This model can envisage an outlook of 
activities in the human system. 
For further investigation of the various inhibitory/interfering molecules in mTSLP based signaling 
in non-transgenic allergic disease models, three types of models could be used: (1) antigen-driven 
models using ovalbumin (OVA), (2) a protease model and (3) a model of Th2-type contact 
hypersensitivity. Enhanced levels of mTSLP have been observed in the OVA-induced airway 
inflammation model, while reduced airway inflammation and goblet cell hyperplasia were observed 
in TSLPR deficient mice (Shami 2005 et al., Zhou et al., 2005) Epicutaneous immunization of mice 
with OVA lead to allergic inflammation in the skin, enhanced infiltration of eosinophils, high Th2 
cytokine levels and OVA-specific serum IgE, all of them are significantly reduced in TSLPR-
deficient mice (R. He et al., 2008). TSLPR deficiency in mice models lead to the attenuation of 
atherosclerotic lesion development by inhibition of Th17 cells and the promotion of regulatory T 
cells (C. Wu et al., 2014). TSLP-TSLPR signal-dependent allergic diarrhea with Th2 cytokine 
production in gastrointestinal tract could also be induced by OVA (Blázquez et al., 2010). In OVA-
induced allergic rhinitis, anti-TSLP antibody treatment neutralized the effects of TSLP and reduced 
its symptoms. Temporary TSLP expression was found to have been induced by mechanical injury in 
the skin (Oyoshi et al., 2010). In the presence of OVA antigen, DCs isolated from the skin of wild-
type mice after mechanical injury elicited increase in IL-4 and IL-13 productions in CD4+ T cells 
with OVA-specific T cell receptor, whereas DCs from the injured skin of TSLPR-deficient mice or 
from the skin of un-injured mice induced the production of both the cytokines at a relatively smaller 
amount (Oyoshi et al., 2010). This study indicates that OVA raised TSLP expression and an 
increased level of TSLP even temporarily in the skin by mechanical injury, induced antigen-derived 
Th2 responses by skin DCs. 
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Proteases also act as allergens. For example, papain, a cysteine protease induced TSLP expression 
at the injected site of the skin in wild-type mice. Here, TSLP expression was dependent on reactive 
oxygen species (ROS), toll-like receptor (TLR) 4 and the adaptor protein Toll/Interleukin -1 
homology (TIR)-domain-containing adaptor-inducing interferon-β (TRIF) (Tang et al., 2010). 
In an experimental model of Th2-type contact hypersensitivity, TSLP was induced using Fluorescein 
isothiocyanate (FITC) as an allergen (a model for human Th2-type contact hypersensitivity). Dibutyl 
phthalate, a solvent component used in this model, induced TSLP expression (Larson et al., 2010, 
Boehme et al., 2008, Shigeno et al.,2009). There was a profound decrease in type-2 immune 
responses in the skin and in antigen-bearing DCs in the draining lymph node following FITC 
treatment in the absence of TSLP responses. The DCs migrated but displayed a decreased capacity 
for promoting CD4+ T cell proliferation (Larson et al., 2010) These studies indicate that the factors 
OVA, proteases and dibutylphthalate act as inducers of TSLP and this leads to allergic inflammation 
in mice. So the above discussed mice models can be used for studying the inhibitors depending on 
the use and various allergic parameters could be evaluated giving us hints about its activity to reduce 
inflammation in mice. Similar models can be trusted as they have been tried before in case of 
screening mutants for IL-4 and IL-13. 
The latest therapies that are available or being studied to treat asthma have been extensively reviewed 
by Cezmi A Akdis (Akdis, 2012) and these involve the following: 
Corticosteroids as inhalers containing corticosteroids and short and long-acting β2-adrenoceptor 
agonists (SABAs and LABAs) are the most prevalent advocated asthma treatments for managing 
Asthma. α-adrenoceptor agonists are used in rhinitis instead to relieve nasal congestion, and non-
sedating H1-antihistamines and topical corticosteroids are well-established control therapies. A 
combination of symptom-relieving and control therapies are used for effective management of most 
allergies. The corticosteroids suppress the Th2-cell-mediated inflammation by transrepression of 
inflammatory cytokines and transexpression of the anti inflammatory cytokines, chemokines and 
adhesion molecules. In smokers and virus-induced exacerbations, the inhaled corticosteroids are 
rendered ineffective.  
β- adrenoreceptor agonists such as Salbutamol and Turbutaline are the most reliable, effective and 
rapid relieving bronchodilators available at present.They act by binding to the β2-adrenoceptor and 
stimulating the adenylate cyclase leading to the production of cyclic adenosine 3′5′-monophosphate 
(cAMP) and activation of protein kinase A. This leads to smooth-muscle relaxation by the 
phosphorylation of myosin light-chain kinase and by opening of Ca2+-dependent K+ (K-Ca) channels, 
thus relieving bronchoconstriction in asthma. 
 5. Discussion 
95 
 
Targeting IgE has been shown in several clinical studies that humanized mAbs bind to the Fc portion 
of the IgE molecule. Omalizumab is one such antibody that binds to the similar sites that IgE 
molecules use to attach to FcεRI and proved to be an effective treatment in patients with poorly 
controlled, moderate to severe allergic asthma or allergic rhinitis. It does not cross-link cell-surface 
expressed IgE. Omalizumab decreases serum concentration of free IgE (unbound) and the expression 
of the high-affinity IgE receptor FcεRI on various immune cells. The reticuloendothelial system 
clears the immune-complexes of IgE and mAb to IgE.  
Mast cells inhibition in the airways and conjunctiva, Sodium cromoglicate (SCG) and Nedocromil 
sodium hinder the allergen-induced early and late-phase responses involving mucosal mast cells 
induced allergic reponses. These drugs inhibit the flux of chloride ions in mast cells, epithelial cells 
and neurons thus increasing their activation threshold. Another attractive target is CD63 suface 
marker on mast cells. These drugs interfere with integrin signalling, localization or trafficking and 
interacts integrins to modify adhesion to fibronectin and vitronectin. A monoclonal antibody 
blocking CD63 inhibits FcεRI-mediated activation of mast cells that are adherent to extracellular 
matrix proteins but not to nonadherent cells. 
Cytokine inhibition inside a network that is responsible for the inflammatory processes that lead to 
asthma and allergy. Immunomodulation of this network through novel biological molecules can 
produce several therapeutic possibilities to suppress the inflammatory activities. mAbs against 
several cytokines have been developed and tried in clinical studies. IL-2Rα (CD25) blocking mAb 
(Daclizumab) is in phase 2 clinical trials and shows efficacy in asthma treatments .It blocks the IL-
2Rα on T cells and inhibits the proinflammatory cytokine generation. It showed no negative effects 
on Treg cell generation in vivo. IL-4 Humanized mAb (Pascolizumab) blocks IL-4 signaling. Phase 
2 studies have been completed but since the only IL-4 targeting approach was found to be non 
effective, and developments were ended. Mutated IL-4 (Pitrakinra) blocks IL-4Rα, common to the 
IL-4 and IL-13 receptors. It showed a reduced allergen response in asthma in the phase 2 clinical 
trials. Targeting of IL-4 and IL-13 simultaneously by AMG-317 showed some efficacy Blocking 
mAb to IL-4Rα, also blocks IL-13 in the clinical phase 2 has been completed and showed efficacy. 
Inhaled oligonucleotide AIR-645 against IL-4Rα, also blocked IL-13 and inhibited effects by 
allergen challenge. This molecule is in clinical development with phase 2 completed Soluble 
recombinant human IL-4 receptor (Altrakincept) during phase 1 and 2 clinical trials showed efficacy 
to control moderate asthma but this was not confirmed during phase 3 trials. Targeting TNF-α is 
important for treatment of non-controlled asthma. TNF-α Infliximab, chimeric mAb has been already 
tested in phase 2 for asthma. TNF-α targeting studies have been stopped due to severe side effects, 
some showed promise while other studies showed no efficacy. The unfavorable risk-benefit ratio is 
unfavourable for this cytokine target and therefore the target may be dropped. OX-40 ligand blocking 
mAb to OX40L is in preclinical development in mice. It inhibits the Th2-type immune responses 
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induced by TSLP but failed to inhibit allergen-induced bronchoconstriction and airway 
hyperresponsiveness (AHR) in subjects with mild allergic asthma. Several such antibodies have been 
developed for IL-17, 25 33 and chemokines and are all in clinical phases in mice. 
The current therapeutic strategies for mitigation of asthma symptoms are affected by the complexity 
of the whole disease spectrum and molecular mechanisms. The biomarkers for subgrouping and 
endotyping are a limitation. Limited information for improvising the existing therapies (for example, 
currently used inhaled steroid and β-adrenergic agonist combination therapy is effective and 
relatively inexpensive) and low patient adherence is another issue. The animal studies in small 
animal models are disappointingly predictive. Most drugs effective in mouse models failed in human 
clinical trials. The impossibility to study two novel biologicals as a combination where one of them 
may potentiate the other, until one of them is approved serves as a limiting factor. In this case one 
of the biologicals may be unlikely to be effective when used alone e.g. cytokine targeting IL-4 etc. 
In this light, new upstream therapeutic like targets like TSLP which are over expressed and affect a 
lot of immune cells during inflammation, need to be focused upon. 
 
The present study yielded results that shall be contributing to the studies aimed at targeting the 
mTSLP/mTSLPR system. Several therapeutic approaches targeting TSLP are in the process of 
clinical trials. These studies add to further information on the possibilities of using well characterized 
cellular model systems for studying mTSLP targeting molecules during in vitro studies. The studies 
yield a low cost and efficient way to produce and test bioactivity of mTSLP and efficacy of its 
mutants in vitro. The findings suggest that the I37E mutant characterized in this study could be 
further improvised with the help of bioinformatics tools to obtain double mutants. The receptor 
interface structural details offer a chance to enable computational molecular docking and production 
of several other mutants. Efforts could also be made to obtain super agonists which bind strongly to 
the TSLPR, even better than mTSLP could and thus can compete with. In addition to the mutant, the 
receptor protein exo domain produced and characterized in these studies gives hope that their local 
administration may inhibit Th2-mediated cardinal features of asthma by altering the function of lung 
DCs. The anti mTSLPR antibody,though non-inhibitory in nature, has been found to bind its target 
and could be used in enhancing knowledge of the key targets TSLP acts in different stages of allergic 
diseases which may be further important in enhancing our comprehension of the TSLPR dynamics 
on the cellular surfaces of various immune cells. TSLP has been shown to activate many other 
immune and structural cells and therefore such data shall help to understand TSLP related signaling 
in response to other cytokine. These studies extend our understanding of biological function of 
TSLP/TSLPR and established the importance of TSLP receptors in atopic diseases. 
Since most prevalent atopic asthma is initiated by inhaled allergen exposure, an OVA/HDM induced 
asthma mouse model system shall provide us further information about the activity of these 
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inhibitory tools in allergen-specific immune responses during pathogenic asthmatic conditions and 
therefore such studies shall be performed in near future. However, since mouse models cannot be 
considered to mimic the full range of clinical manifestations of asthma in humans, humans clinical 
studies will be required before TSLP can be beyond doubt regarded as a central regulator of allergic 
asthma. The identification and comprehension of various allergic inflammatory pathways affected 
by TSLP is therefore a relevant and open dynamic area of active study. 
In conclusion, the findings in this thesis provide an insightful understanding about mTSLP based 
signaling responses during the inflammatory process. The goals of this study to generate mTSLP 
responsive cell based models which provide quantifiable data and to generate tools to impede mTSLP 
mediated signaling by antagonists has been met successfully. It can be envisaged that employing 
these cellular models and tools generated in this study, further investigations could be carried on to 
study the mTSLP action on various immune cells at molecular level. Since mTSLP influences the 
immune cell homeostasis at the body’s barrier surfaces in association with various chemokines, it 
engages various immune cells to initiate the inflammatory process during asthma. In this regard, 
these cellular models could be utilized to investigate the role of various allergens and toxic chemicals 
in the inflammatory processes. These studies could also provide a foresight into further development 
of natural human cell based models to study hTSLP activity.  
In order to understand and utilize the knowledge about biological intercellular signaling by TSLP, 
specific information about the promotion and control of TSLPR expression dynamics on various 
cells must be delineated. In this light it’s also important to decrypt whether TSLP evokes similar 
signaling pathways within different cells. The antibody generated in this study could bind 
successfully to the surface expressed TSLPR on various immune cells and thus it could be used for 
probing the dynamics of mTSLPR expression towards cytokine treatments.  
The administration of the mutant in vitro resulted in down regulation of inflammation markers such 
as OX40, CD80 and CD86 ligands on the surface of DCs as well as reduction of STAT1 promoted 
signaling in TSLP responsive Ba/F3 cellular model. These results increase our understanding of the 
biological function of TSLP/TSLPR signaling and highlight the importance of TSLP in initiation 
and activation of Th2 skewed responses in atopic diseases. As an improvised study, the natural model 
could be used to study the effects of TSLP inhibition using the antagonists on various other signaling 
pathways. 
The heterogeneity of various genetic and environmental factors responsible for phenotypic 
expression in Asthma complicates the desire to design a uniform effective therapy for all the patients. 
Therefore it becomes essential to find and target upstream molecules involved in cellular immune as 
a central axis, which makes therapeutic targeting of TSLP desirable. It will be interesting to 
determine whether the administration of soluble exo-mTSLPR domain and the mutant I37E mTSLP 
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at the allergen-challenge phase has similar therapeutic effects in OVA/HDM mouse models of 
Asthma. This study, therefore leaves us open for further interrogation of targeted antagonistic 
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Appendix I. Plasmid Maps 
 
1. pcDNA3.1 mTSLPR-His 6X 
 
















5. pMAL-c2X-mTSLP (In mutant form I37E, Isoleucine replaced by glutamate at 
position 37 by PCR) 
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